Review



r1441g mutants  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Addgene inc r1441g mutants
    R1441g Mutants, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/r1441g mutants/product/Addgene inc
    Average 92 stars, based on 6 article reviews
    r1441g mutants - by Bioz Stars, 2026-02
    92/100 stars

    Images



    Similar Products

    90
    Thermo Fisher a commercial taqman assay for lrrk2 r1441g on a step one plus real-time pcr system (life tech.)

    A Commercial Taqman Assay For Lrrk2 R1441g On A Step One Plus Real Time Pcr System (Life Tech.), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a commercial taqman assay for lrrk2 r1441g on a step one plus real-time pcr system (life tech.)/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    a commercial taqman assay for lrrk2 r1441g on a step one plus real-time pcr system (life tech.) - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    92
    Addgene inc r1441g mutants

    R1441g Mutants, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/r1441g mutants/product/Addgene inc
    Average 92 stars, based on 1 article reviews
    r1441g mutants - by Bioz Stars, 2026-02
    92/100 stars
      Buy from Supplier

    90
    Denali Therapeutics lrrk2 r1441g ki a549 cells
    ( A and B ) <t>A549</t> cells were transfected with siRNA targeting <t>LRRK2</t> and its Rab substrates, lysed 3 days after transfection, and the levels of pT73 Rab10 and LRRK2 were quantified using Meso Scale Discovery (MSD)-based analysis. The MSD signal was normalized to the protein concentration, and data are shown on a log 2 scale as the mean ± SEM; n=3 independent experiments, and statistical significance was determined using one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test. ( C ) RAB12 mRNA levels were quantified using RT-qPCR-based analysis and normalized to GAPDH following transfection with siRNAs targeting a scramble sequence or RAB12. Data are shown as the mean ± SEM; n=3 independent experiments, and statistical significance was determined using paired t-test. ( D ) The levels of pT73 Rab10, Rab10, Rab12, LRRK2, and Rab8a following siRNA-mediated knockdown of LRRK2 and its Rab substrates were assessed in A549 cells by western blot analysis. Shown is a representative immunoblot with GAPDH as a loading control. ( E and F ) The immunoblot signals from multiple experiments were quantified, and the Rab12 and Rab10 signal was normalized to GAPDH, normalized to the median within each batch and expressed as a fold change compared to the scramble control; data are shown as the mean ± SEM; n=3 independent experiments. Statistical significance was determined using unpaired t-test. *p<0.05, **p<0.01, ****p<0.0001. Figure 1—source data 1. Raw data files for western blots. Figure 1—source data 2. Annotated western blots.
    Lrrk2 R1441g Ki A549 Cells, supplied by Denali Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lrrk2 r1441g ki a549 cells/product/Denali Therapeutics
    Average 90 stars, based on 1 article reviews
    lrrk2 r1441g ki a549 cells - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Synthego Inc crispr/cas9- mediated knock- in of lrrk2 r1441g or vps35 d620n
    ( A and B ) <t>A549</t> cells were transfected with siRNA targeting <t>LRRK2</t> and its Rab substrates, lysed 3 days after transfection, and the levels of pT73 Rab10 and LRRK2 were quantified using Meso Scale Discovery (MSD)-based analysis. The MSD signal was normalized to the protein concentration, and data are shown on a log 2 scale as the mean ± SEM; n=3 independent experiments, and statistical significance was determined using one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test. ( C ) RAB12 mRNA levels were quantified using RT-qPCR-based analysis and normalized to GAPDH following transfection with siRNAs targeting a scramble sequence or RAB12. Data are shown as the mean ± SEM; n=3 independent experiments, and statistical significance was determined using paired t-test. ( D ) The levels of pT73 Rab10, Rab10, Rab12, LRRK2, and Rab8a following siRNA-mediated knockdown of LRRK2 and its Rab substrates were assessed in A549 cells by western blot analysis. Shown is a representative immunoblot with GAPDH as a loading control. ( E and F ) The immunoblot signals from multiple experiments were quantified, and the Rab12 and Rab10 signal was normalized to GAPDH, normalized to the median within each batch and expressed as a fold change compared to the scramble control; data are shown as the mean ± SEM; n=3 independent experiments. Statistical significance was determined using unpaired t-test. *p<0.05, **p<0.01, ****p<0.0001. Figure 1—source data 1. Raw data files for western blots. Figure 1—source data 2. Annotated western blots.
    Crispr/Cas9 Mediated Knock In Of Lrrk2 R1441g Or Vps35 D620n, supplied by Synthego Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crispr/cas9- mediated knock- in of lrrk2 r1441g or vps35 d620n/product/Synthego Inc
    Average 90 stars, based on 1 article reviews
    crispr/cas9- mediated knock- in of lrrk2 r1441g or vps35 d620n - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    91
    Addgene inc r1441g
    ( A–D ) Microscale thermophoresis of Rab12 binding to fluorescently labeled LRRK2 Armadillo domain (residues 1–552) wild type ( A ) or bearing the indicated mutations at Site #1: K439E ( B ) or Site #3: E240R ( C ) and F283A ( D ). Purified Rab12 was serially diluted and then NHS-RED-labeled-LRRK2 Armadillo (final concentration 100 nM) was added. Graphs show mean and SEM from two independent measurements, each the average of two replicate runs. ( E ) Immunoblot of anti-FLAG antibody immunoprecipitation of FLAG-LRRK2 wild type or indicated Site #3 mutants with endogenous or co-expressed HA-Rab12 protein in HEK293 cells. Lysate inputs (1.5%) are shown at left; membranes were probed with anti-FLAG or anti-Rab12 antibodies. ( F ) Quantitation of two independent experiments carried out in duplicate as in ( E ). ****p<0.0001 for LRRK2 E240R and S244R relative to LRRK2 WT by one-way ANOVA. ( G ) Immunoblot analysis of 293T cells transfected with LRRK2 R1441C or K17/18A <t>R1441G</t> and GFP, GFP-Rab8, or GFP-Rab12 for 36 hr; +/-MLi2 (200 nM for 2 hr). ( H ) Quantitation of the fraction of phosphorylated Rab10 from immunoblots as in ( G ) normalized to respective total Rab10 levels, normalized to LRRK2 R1441C+GFP-Rab12. Error bars indicate SEM from two independent experiments; **p=0.003 for LRRK2 R1441C GFP and GFP-Rab12, **p=0.0044 for LRRK2 K17/18A R1441G GFP and GFP-Rab12, ns = 0.6 by Student’s t -test. Figure 8—source data 1. Raw/annotated gels for .
    R1441g, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/r1441g/product/Addgene inc
    Average 91 stars, based on 1 article reviews
    r1441g - by Bioz Stars, 2026-02
    91/100 stars
      Buy from Supplier

    90
    Jackson Laboratory lrrk2 r1441g tg mice
    <t>LRRK2</t> G2019S mutation deregulates the TH–DA pathway, leading to DA neuron vulnerability. A – G LRRK2 enhances TH expression in PC12 cells in an LRRK2 kinase activity-dependent manner. A , C and F Representative Western blot data of up-regulated TH levels in PC12 cells under transient overexpression of WT, mutant G2019S or 3KD LRRK2. A FL LRRK2, C LRRK2 RCK domains and F LRRK2 kinase domain. B , D and G , Densitometric analysis of TH protein bands of Western blot gels in A , C and F , respectively. *, at least P < 0.01, compared with arbitrary value of TH protein bands of GFP-transfected control cells. E Quantitative real-time RT-PCR analysis of TH expression in PC12 cells under overexpression of WT, mutant G2019S or 3KD LRRK2 RCK domains. * P < 0.01, compared with relative TH expression level of GFP-transfected control cells. H Expression of WT and mutant G2019S LRRK2 RCK domains impair PC12 cell viability, which can be partially rescued by 500 µM GSH treatment. *, at least P < 0.01, compared with cell viability of the respective WT or G2019S RCK domains transfected PC12 cells in the absence of GSH treatment. (I–P) Stable transfection of LRRK2 up-regulates TH and DA levels, sensitizing human dopaminergic SH-SY5Y cells to stress challenges. I Representative Western blot TH protein bands in SH-SY5Y cells stably transfected with empty vector, WT or mutant G2019S FL LRRK2. J Densitometric analysis of Western blot TH protein bands in I . * P < 0.001, compared with arbitrary value of TH bands of empty vector transfected control SH-SY5Y cells. K and L Mutant G2019S LRRK2-induced DA content increase in stably transfected SH-SY5Y cells can be abrogated by treatment with 2 mM α-MT, a specific TH inhibitor. K Quantitative analysis of DA content by HPLC, *, at least P < 0.05, compared with DA content of the respective cells in the absence of α-MT. L Representative HPLC chromatography of DA peaks. M Quantitative real-time RT-PCR analysis of TH and LRRK2 expression level in stably transfected SH-SY5Y cells. *, at least P < 0.01, compared with TH and LRRK2 expression levels of empty vector transfected SH-SY5Y cells. N Stable transfection of mutant G2019S LRRK2 sensitizes SH-SY5Y cells to H 2 O 2 challenge. *, at least P < 0.05, compared with cell viability of empty vector transfected SH-SY5Y cells treated with the respective dosage of H 2 O 2 . ( O and P ) 2 mM α-MT treatment alleviates LRRK2-induced SH-SY5Y cell viability impairment under 100 µM Fe 2+ ( O ) or 100 µM Fe 3+ ( P ) challenges. *, at least P < 0.05, compared with cell death rate of the respective stable cells without iron species challenges. #, at least P < 0.05, compared with cell death rate of respective SH-SY5Y cells under the respective iron species challenges
    Lrrk2 R1441g Tg Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lrrk2 r1441g tg mice/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    lrrk2 r1441g tg mice - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Addgene inc recombinant dna reagent pcmv5 flag-lrrk2 k17a/k18a/r1441g

    Recombinant Dna Reagent Pcmv5 Flag Lrrk2 K17a/K18a/R1441g, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant dna reagent pcmv5 flag-lrrk2 k17a/k18a/r1441g/product/Addgene inc
    Average 90 stars, based on 1 article reviews
    recombinant dna reagent pcmv5 flag-lrrk2 k17a/k18a/r1441g - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Jackson Laboratory hlrrk2 r1441g transgenic mice fvb/n-tg ( lrrk2 *r1441g)135cjli/j
    Detection of <t>hLRRK2</t> and hLRRK2 <t>R1441G</t> expression and GTPase activity in Tg mice. A Real-time PCR assays of hLRRK2 and hLRRK2 R1441G mRNA expression in the brains of Tg mice. Data represent relative mRNA levels (mean ± SEM, n = 8) normalized to mouse apoB and are expressed in arbitrary units. B <t>LRRK2</t> protein expression in the brains of non-Tg and Tg mice (n = 3). C hLRRK2 R1441G HEM and HOM mice lost less weight than non-Tg mice. Data are presented as the mean ± SEM (n = 6). D GTPase activity was measured using an enzyme-linked inorganic phosphate assay (ELIPA; n = 3). E Disruption of LRRK2 Ser935 phosphorylation in the brains of hLRRK2 , R1441G HOM mice. Total lysates from the brains of 12-month-old hLRRK2 R1441G HOM mice were analyzed by western blotting for phosphorylation of LRRK2 at Ser935; actin was used as a loading control. *Significant effect, p < 0.05; **significant effect, p < 0.01; ***significant effect, p < 0.005; ****significant effect, p < 0.001
    Hlrrk2 R1441g Transgenic Mice Fvb/N Tg ( Lrrk2 *R1441g)135cjli/J, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hlrrk2 r1441g transgenic mice fvb/n-tg ( lrrk2 *r1441g)135cjli/j/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    hlrrk2 r1441g transgenic mice fvb/n-tg ( lrrk2 *r1441g)135cjli/j - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Jackson Laboratory c57bl/6j-tg(lrrk2*r1441g)3imjff/j mice
    Detection of <t>hLRRK2</t> and hLRRK2 <t>R1441G</t> expression and GTPase activity in Tg mice. A Real-time PCR assays of hLRRK2 and hLRRK2 R1441G mRNA expression in the brains of Tg mice. Data represent relative mRNA levels (mean ± SEM, n = 8) normalized to mouse apoB and are expressed in arbitrary units. B <t>LRRK2</t> protein expression in the brains of non-Tg and Tg mice (n = 3). C hLRRK2 R1441G HEM and HOM mice lost less weight than non-Tg mice. Data are presented as the mean ± SEM (n = 6). D GTPase activity was measured using an enzyme-linked inorganic phosphate assay (ELIPA; n = 3). E Disruption of LRRK2 Ser935 phosphorylation in the brains of hLRRK2 , R1441G HOM mice. Total lysates from the brains of 12-month-old hLRRK2 R1441G HOM mice were analyzed by western blotting for phosphorylation of LRRK2 at Ser935; actin was used as a loading control. *Significant effect, p < 0.05; **significant effect, p < 0.01; ***significant effect, p < 0.005; ****significant effect, p < 0.001
    C57bl/6j Tg(Lrrk2*R1441g)3imjff/J Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c57bl/6j-tg(lrrk2*r1441g)3imjff/j mice/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    c57bl/6j-tg(lrrk2*r1441g)3imjff/j mice - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet:

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques: Standard Deviation

    ( a ) Peripheral blood mononuclear cells (PBMCs) processing for different applications. 40 ml of blood were drawn from subjects of a LRRK2 clinical cohort from Spain (n=174) encompassing G2019S L2PD patients (n=37), G2019S L2NMCs (n=27), R1441G L2PD patients (n=14), R1441G L2NMCs (n=11), iPD (n=40), and controls (n=45). ( b ) After PBMCs isolation, homogenization, and protein digestion, a total of 3,815 proteins were identified by DIA-MS on an EZ-Exploris 480 mass-spectrometer (Thermo), and 10,288 phospho-sites after phospho-enrichment. For the group differential analysis, we only considered proteins and phospho-sites mapped by ≥2 different peptides (Spetronaut), and with <30% imputation, with a significance cut-off of log 2 FC>|0.6| and a multiple testing adjusted P<0.05. Data deconvolution and interactive representation of findings were done using the Curtain / Curtain PTM Tool, and gene ontology was assessed by Metascape. Using machine learning, we identified an 18-feature G2019S phospho-/protein signature able to discriminate G2019S L2PD, G2019S L2NMCs, and controls. By immunoblot, we assessed pSer106 RAB12 / total RAB12 levels in PBMCs from a subject of subjects (n=48) after 1 year of follow-up, including G2019S L2PD (n=12), G2019S L2NMCs (n=6), iPD (n=15) and controls (n=15). Lastly, in freshly isolated PBMCs from a second subset of subjects (n=10) encompassing G2019S L2PD (n=3), R1441G L2PD (n=1), iPD (n=1) and healthy controls (n=5), treated with DMSO or the MLi-2 LRRK2 inhibitor, we performed an LRRK2 kinase assay measuring pSer106 RAB12 / total RAB12 levels.

    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet: ( a ) Peripheral blood mononuclear cells (PBMCs) processing for different applications. 40 ml of blood were drawn from subjects of a LRRK2 clinical cohort from Spain (n=174) encompassing G2019S L2PD patients (n=37), G2019S L2NMCs (n=27), R1441G L2PD patients (n=14), R1441G L2NMCs (n=11), iPD (n=40), and controls (n=45). ( b ) After PBMCs isolation, homogenization, and protein digestion, a total of 3,815 proteins were identified by DIA-MS on an EZ-Exploris 480 mass-spectrometer (Thermo), and 10,288 phospho-sites after phospho-enrichment. For the group differential analysis, we only considered proteins and phospho-sites mapped by ≥2 different peptides (Spetronaut), and with <30% imputation, with a significance cut-off of log 2 FC>|0.6| and a multiple testing adjusted P<0.05. Data deconvolution and interactive representation of findings were done using the Curtain / Curtain PTM Tool, and gene ontology was assessed by Metascape. Using machine learning, we identified an 18-feature G2019S phospho-/protein signature able to discriminate G2019S L2PD, G2019S L2NMCs, and controls. By immunoblot, we assessed pSer106 RAB12 / total RAB12 levels in PBMCs from a subject of subjects (n=48) after 1 year of follow-up, including G2019S L2PD (n=12), G2019S L2NMCs (n=6), iPD (n=15) and controls (n=15). Lastly, in freshly isolated PBMCs from a second subset of subjects (n=10) encompassing G2019S L2PD (n=3), R1441G L2PD (n=1), iPD (n=1) and healthy controls (n=5), treated with DMSO or the MLi-2 LRRK2 inhibitor, we performed an LRRK2 kinase assay measuring pSer106 RAB12 / total RAB12 levels.

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques: Isolation, Homogenization, Mass Spectrometry, Western Blot, Kinase Assay

    ( a ) Barplots showing the numbers of differential proteins in different pairwise comparisons involving G2019S carriers, R1441G carriers, iPD, and controls, with up-regulated proteins in dark grey, and down-regulated in light grey. All cohorts were run in parallel, with balanced study groups per run, blind to the operator, and using 1 quantile normalisation (Limma). The significance cut-off was set at a log 2 FC>|0.6| and a multiple testing adjusted P<0.05. ( b ) Volcano plot of the proteome differential analysis in G2019S L2PD vs healthy controls, with Curtain weblinks to access raw and differential analysis data, showing proteins up-regulated in G2019S L2PD as red dots on the right, and proteins up-regulated in controls (i.e., down-regulated in G2019S L2PD) as red dots on the left ( Curtain ). A legend colour code applying to all panels is shown at the bottom of the figure, depicting statistically significant hits as red dots. ( c ) Volcano plot of the proteome differential analysis in G2019S carriers as a whole, i.e., L2PD and L2NMCs, vs healthy controls ( Curtain ). ( d ) Volcano plot showing the proteome differential analysis between G2019S L2NMCs and healthy controls ( Curtain ). ( e ) Volcano plot representing the proteome comparison between G2019S L2NMCs and G2019S L2PD. A Venn diagram at the bottom of the figure shows the overlap of differential hits in PD-manifesting and non-manifesting G2019S carriers ( Curtain ).

    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet: ( a ) Barplots showing the numbers of differential proteins in different pairwise comparisons involving G2019S carriers, R1441G carriers, iPD, and controls, with up-regulated proteins in dark grey, and down-regulated in light grey. All cohorts were run in parallel, with balanced study groups per run, blind to the operator, and using 1 quantile normalisation (Limma). The significance cut-off was set at a log 2 FC>|0.6| and a multiple testing adjusted P<0.05. ( b ) Volcano plot of the proteome differential analysis in G2019S L2PD vs healthy controls, with Curtain weblinks to access raw and differential analysis data, showing proteins up-regulated in G2019S L2PD as red dots on the right, and proteins up-regulated in controls (i.e., down-regulated in G2019S L2PD) as red dots on the left ( Curtain ). A legend colour code applying to all panels is shown at the bottom of the figure, depicting statistically significant hits as red dots. ( c ) Volcano plot of the proteome differential analysis in G2019S carriers as a whole, i.e., L2PD and L2NMCs, vs healthy controls ( Curtain ). ( d ) Volcano plot showing the proteome differential analysis between G2019S L2NMCs and healthy controls ( Curtain ). ( e ) Volcano plot representing the proteome comparison between G2019S L2NMCs and G2019S L2PD. A Venn diagram at the bottom of the figure shows the overlap of differential hits in PD-manifesting and non-manifesting G2019S carriers ( Curtain ).

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques: Comparison

    Venn diagrams depicting common and specific hits in various groups as compared to healthy controls. ( a ) Differential hits found at various G2019S carrier groups, PD manifesting and non-manifesting, compared to controls. ( b ) Hits from various R1441G carrier groups, symptomatic and asymptomatic, vs controls. ( c ) Common and specific hits were observed in the different PD patient groups, i.e., G2019S L2PD, R1441G L2PD, and iPD. ( d ) Differential hits among L2PD patients carrying either the G2019S or the R1441G mutations, stratified by up and down-regulated hits. ( e ) Differential hits among L2NMCs carrying either the G2019S or the R1441G mutations, as analysed segregated by up and down-regulated hits.

    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet: Venn diagrams depicting common and specific hits in various groups as compared to healthy controls. ( a ) Differential hits found at various G2019S carrier groups, PD manifesting and non-manifesting, compared to controls. ( b ) Hits from various R1441G carrier groups, symptomatic and asymptomatic, vs controls. ( c ) Common and specific hits were observed in the different PD patient groups, i.e., G2019S L2PD, R1441G L2PD, and iPD. ( d ) Differential hits among L2PD patients carrying either the G2019S or the R1441G mutations, stratified by up and down-regulated hits. ( e ) Differential hits among L2NMCs carrying either the G2019S or the R1441G mutations, as analysed segregated by up and down-regulated hits.

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques:

    Consistently across the study, the significance cut-off for R1441G proteome and phospho- proteome analyses was also set at a log 2 FC>|0.6| and a multiple testing adj. P<0.05. A legend colour code applying to all panels is shown at the bottom of the figure, depicting statistically significant hits as red dots. ( a ) Volcano plot of the proteome differential analysis in R1441G L2PD vs healthy controls, with Curtain weblinks to access raw and differential analysis data, showing proteins up-regulated in R1441G L2PD as red dots on the right, and proteins up-regulated in controls (i.e., down-regulated in R1441G L2PD) as red dots on the left ( Curtain ). ( b ) Volcano plot of the proteome differential analysis in R1441G carriers as a whole, i.e., L2PD and L2NMCs, vs healthy controls ( Curtain ). ( c ) Volcano plot showing the proteome differential analysis between R1441G L2NMCs and healthy controls ( Curtain ). ( d ) Volcano plot representing the proteome comparison between R1441G L2NMCs and R1441G L2PD ( Curtain ). ( e ) Volcano plot of the phospho-proteome differential analysis between R1441G L2PD vs controls ( Curtain PTM ). ( f ) Volcano plot of the phospho-proteome comparison of R1441G L2NMCs and controls ( Curtain PTM ).

    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet: Consistently across the study, the significance cut-off for R1441G proteome and phospho- proteome analyses was also set at a log 2 FC>|0.6| and a multiple testing adj. P<0.05. A legend colour code applying to all panels is shown at the bottom of the figure, depicting statistically significant hits as red dots. ( a ) Volcano plot of the proteome differential analysis in R1441G L2PD vs healthy controls, with Curtain weblinks to access raw and differential analysis data, showing proteins up-regulated in R1441G L2PD as red dots on the right, and proteins up-regulated in controls (i.e., down-regulated in R1441G L2PD) as red dots on the left ( Curtain ). ( b ) Volcano plot of the proteome differential analysis in R1441G carriers as a whole, i.e., L2PD and L2NMCs, vs healthy controls ( Curtain ). ( c ) Volcano plot showing the proteome differential analysis between R1441G L2NMCs and healthy controls ( Curtain ). ( d ) Volcano plot representing the proteome comparison between R1441G L2NMCs and R1441G L2PD ( Curtain ). ( e ) Volcano plot of the phospho-proteome differential analysis between R1441G L2PD vs controls ( Curtain PTM ). ( f ) Volcano plot of the phospho-proteome comparison of R1441G L2NMCs and controls ( Curtain PTM ).

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques: Comparison

    Curtain weblinks provide access to raw and differential analysis data. The legend colour code shows hits categorisation based on statistical significance and applies to all the panels. ( a ) Volcano plot of the proteome analysis in iPD vs controls showing no differential hit under the statistical cut-off used ( Curtain ). ( b ) Volcano plot representing protein differences between iPD and G2019S L2PD, showing iPD up-regulated proteins as red dots on the left ( Curtain ). ( c ) Volcano plot representing protein changes between iPD and R1441G L2PD, with iPD up-regulated proteins as red dots on the left, and iPD down-regulated (i.e., up-regulated in R1441G L2PD) as red dots on the right ( d ) Volcano plot of the phospho-proteome analysis in iPD vs controls showing no differential hit, despite being iPD the groups with larger sample size in the study ( Curtain PTM ). ( e ) Volcano plot representing phospho-protein differences between iPD and G2019S L2PD, with proteins hyper-phosphorylated in G2019S L2PD as red dots on the right, showing pSer106 RAB12 as top hit, and proteins hyper-phosphorylated in iPD (i.e., hypo-phosphorylated in G2019S L2PD) as red dots on the left ( Curtain PTM ). ( f ) Similar analysis as in the previous panel, here comparing the phospho-proteome comparison between iPD and R1441G L2PD ( Curtain PTM ).

    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet: Curtain weblinks provide access to raw and differential analysis data. The legend colour code shows hits categorisation based on statistical significance and applies to all the panels. ( a ) Volcano plot of the proteome analysis in iPD vs controls showing no differential hit under the statistical cut-off used ( Curtain ). ( b ) Volcano plot representing protein differences between iPD and G2019S L2PD, showing iPD up-regulated proteins as red dots on the left ( Curtain ). ( c ) Volcano plot representing protein changes between iPD and R1441G L2PD, with iPD up-regulated proteins as red dots on the left, and iPD down-regulated (i.e., up-regulated in R1441G L2PD) as red dots on the right ( d ) Volcano plot of the phospho-proteome analysis in iPD vs controls showing no differential hit, despite being iPD the groups with larger sample size in the study ( Curtain PTM ). ( e ) Volcano plot representing phospho-protein differences between iPD and G2019S L2PD, with proteins hyper-phosphorylated in G2019S L2PD as red dots on the right, showing pSer106 RAB12 as top hit, and proteins hyper-phosphorylated in iPD (i.e., hypo-phosphorylated in G2019S L2PD) as red dots on the left ( Curtain PTM ). ( f ) Similar analysis as in the previous panel, here comparing the phospho-proteome comparison between iPD and R1441G L2PD ( Curtain PTM ).

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques: Comparison

    Comparative gene ontology (GO) enrichment analysis of the differential proteins observed in G2019S and R1441G L2PD was done in Metascape under a multiple testing adj. P<0.05, here denoted as a dashed red line. ( a ) GO enrichment plot in G2019S L2PD vs controls. ( b ) GO enrichment plot in R1441G L2PD vs controls. Proteome changes related to both mutations showed affection of similar functional terms affecting the endolysosomal pathway (red asterisks), protein homeostasis (green), and mitochondria function (blue).

    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet: Comparative gene ontology (GO) enrichment analysis of the differential proteins observed in G2019S and R1441G L2PD was done in Metascape under a multiple testing adj. P<0.05, here denoted as a dashed red line. ( a ) GO enrichment plot in G2019S L2PD vs controls. ( b ) GO enrichment plot in R1441G L2PD vs controls. Proteome changes related to both mutations showed affection of similar functional terms affecting the endolysosomal pathway (red asterisks), protein homeostasis (green), and mitochondria function (blue).

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques: Functional Assay

    Immunoblot assessment of pSer106 RAB12 phosphorylation levels in >1-year follow-up PBMC samples from part of the LRRK2 subcohort from Clínic-Barcelona (n=48), including G2019S L2PD (n=12), G2019S L2NMCs (n=6), iPD (n=15), and controls (n=15). ( a ) Schematic workflow of immunoblot assessment and representative blot from 5 different blots shown in the Supplement. (*) Denotes intergel control. ( b ) dot plots comparing pSer106 RAB12 / Total RAB12 levels obtained by DIA-MS at the entire LRRK2 clinical cohort (n=174) on the left, and by immunoblot of part of the Clínic-Barcelona cohort after 1-year of follow-up (n=48) in G2019S carriers on the right. In each plot, overall intergroup differences were assessed using the Kruskal-Wallis test followed by post-hoc Dunn’s test to assess for pSer106 RAB12 / Total RAB12 differences in G2019S carriers. ( c ) Representative immunoblot analysis of pSer106 RAB12 / Total RAB12 and pThr73 RAB10 / Total RAB10 using technical replicates from additional freshly collected PBMCs from one R1441G L2PD, one G2019S L2PD, one iPD and 3 controls (expanded to a total n=10 subjects in the Supplement), treated with DMSO or the MLi-2 LRRK2 inhibitor (200 nM, 30 min), showing a diminishment of pSer106 RAB12 phosphorylation levels after LRRK2 inhibition by MLi-2 treatment.

    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet: Immunoblot assessment of pSer106 RAB12 phosphorylation levels in >1-year follow-up PBMC samples from part of the LRRK2 subcohort from Clínic-Barcelona (n=48), including G2019S L2PD (n=12), G2019S L2NMCs (n=6), iPD (n=15), and controls (n=15). ( a ) Schematic workflow of immunoblot assessment and representative blot from 5 different blots shown in the Supplement. (*) Denotes intergel control. ( b ) dot plots comparing pSer106 RAB12 / Total RAB12 levels obtained by DIA-MS at the entire LRRK2 clinical cohort (n=174) on the left, and by immunoblot of part of the Clínic-Barcelona cohort after 1-year of follow-up (n=48) in G2019S carriers on the right. In each plot, overall intergroup differences were assessed using the Kruskal-Wallis test followed by post-hoc Dunn’s test to assess for pSer106 RAB12 / Total RAB12 differences in G2019S carriers. ( c ) Representative immunoblot analysis of pSer106 RAB12 / Total RAB12 and pThr73 RAB10 / Total RAB10 using technical replicates from additional freshly collected PBMCs from one R1441G L2PD, one G2019S L2PD, one iPD and 3 controls (expanded to a total n=10 subjects in the Supplement), treated with DMSO or the MLi-2 LRRK2 inhibitor (200 nM, 30 min), showing a diminishment of pSer106 RAB12 phosphorylation levels after LRRK2 inhibition by MLi-2 treatment.

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques: Western Blot, Inhibition

    Full immunoblot assessment of pSer106 RAB12 phosphorylation levels, and expression levels of RAB9A and LAMP1, using >1-year follow-up PBMC samples from a subset of the LRRK2 cohort from Clínic-Barcelona (n=48), including G2019S L2PD (n=12), G2019S L2NMCs (n=6), iPD (n=15), and controls (n=15). Dot plots representing normalised levels after the band densitometric analysis for the various studied makers in all subjects studied in duplicates as it follows, pSer106 RAB12 / Total RAB12; RAB9A / GADPH; and LAMP1 / GADPH, all of them double normalised to the same intergel control also measured in duplicates. In each plot, overall intergroup differences were assessed using Kruskal-Wallis test followed by post-hoc Dunn’s test under an FDR multiple testing adjusted P<0.05. (*) Denotes intergel control.

    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet: Full immunoblot assessment of pSer106 RAB12 phosphorylation levels, and expression levels of RAB9A and LAMP1, using >1-year follow-up PBMC samples from a subset of the LRRK2 cohort from Clínic-Barcelona (n=48), including G2019S L2PD (n=12), G2019S L2NMCs (n=6), iPD (n=15), and controls (n=15). Dot plots representing normalised levels after the band densitometric analysis for the various studied makers in all subjects studied in duplicates as it follows, pSer106 RAB12 / Total RAB12; RAB9A / GADPH; and LAMP1 / GADPH, all of them double normalised to the same intergel control also measured in duplicates. In each plot, overall intergroup differences were assessed using Kruskal-Wallis test followed by post-hoc Dunn’s test under an FDR multiple testing adjusted P<0.05. (*) Denotes intergel control.

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques: Western Blot, Expressing

    Full immunoblot analysis of pSer106 RAB12 / Total RAB12 and pThr73 RAB10 / Total RAB10 using two technical replicates of PBMC lysates from G2019S L2PD (n=3) and healthy controls (n=3), treated with DMSO or the MLi-2 LRRK2 inhibitor (200 nM, 30 min), showing a diminishment of pSer106 RAB12 phosphorylation levels after LRRK2 inhibition by MLi-2 treatment.

    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet: Full immunoblot analysis of pSer106 RAB12 / Total RAB12 and pThr73 RAB10 / Total RAB10 using two technical replicates of PBMC lysates from G2019S L2PD (n=3) and healthy controls (n=3), treated with DMSO or the MLi-2 LRRK2 inhibitor (200 nM, 30 min), showing a diminishment of pSer106 RAB12 phosphorylation levels after LRRK2 inhibition by MLi-2 treatment.

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques: Western Blot, Inhibition

    After comparing the performance of several models, we applied supported vector machine (SVM) learning, adjusted by unbalanced groups using the Synthetic Minority Over-sampling Technique (SMOTE), corrected from overfitting with 5-fold cross-validation, identified cross-group differential proteins and phospho-proteins by ANOVA and Recursive Feature Elimination with Cross-Validation (RFECV), and refined informative combinations to the minimal numbers of features yielding the maximal balanced accuracy by the Montecarlo Tree Search (MCTS) method. ( a ) 18-feature G2019S phospho-/protein best classifier identified in G2019S carriers, both PD-manifesting and non-manifesting subjects, and healthy controls. Red dots indicate individual features correlating with disease severity (UPDRS-III) (See next Figure). ( b ) Relative contribution of the different proteins (n=15) and phospho-sites (n=3), including pSer106 RAB12, from the 18-feature G2019S classifier on the upper bar plot; Metascape gene ontology enrichment analysis of the 18-features G2019S signature lower bar plot. ( c ) Receiver Operating Curve (ROC) analysis of the 18-feature G2019S phospho-/protein signature showing an overall balanced accuracy of 0.957 to discriminate G2019S L2PD, G2019S L2NMCs and controls, specifically with an area under the curve (AUC) of 1.00 between G2019S L2PD and controls, and 0.99 between G2019S L2NMCs and controls. ( d ) Principal component analysis (PCA) based on the 18-feature G2019S phospho-/protein classifier in G2019S carriers and healthy controls showing distinct group profiles based on LRRK2 mutation and disease status, with G2019S L2NMCs in between G2019S L2PD and controls, consistent with their disease status.

    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet: After comparing the performance of several models, we applied supported vector machine (SVM) learning, adjusted by unbalanced groups using the Synthetic Minority Over-sampling Technique (SMOTE), corrected from overfitting with 5-fold cross-validation, identified cross-group differential proteins and phospho-proteins by ANOVA and Recursive Feature Elimination with Cross-Validation (RFECV), and refined informative combinations to the minimal numbers of features yielding the maximal balanced accuracy by the Montecarlo Tree Search (MCTS) method. ( a ) 18-feature G2019S phospho-/protein best classifier identified in G2019S carriers, both PD-manifesting and non-manifesting subjects, and healthy controls. Red dots indicate individual features correlating with disease severity (UPDRS-III) (See next Figure). ( b ) Relative contribution of the different proteins (n=15) and phospho-sites (n=3), including pSer106 RAB12, from the 18-feature G2019S classifier on the upper bar plot; Metascape gene ontology enrichment analysis of the 18-features G2019S signature lower bar plot. ( c ) Receiver Operating Curve (ROC) analysis of the 18-feature G2019S phospho-/protein signature showing an overall balanced accuracy of 0.957 to discriminate G2019S L2PD, G2019S L2NMCs and controls, specifically with an area under the curve (AUC) of 1.00 between G2019S L2PD and controls, and 0.99 between G2019S L2NMCs and controls. ( d ) Principal component analysis (PCA) based on the 18-feature G2019S phospho-/protein classifier in G2019S carriers and healthy controls showing distinct group profiles based on LRRK2 mutation and disease status, with G2019S L2NMCs in between G2019S L2PD and controls, consistent with their disease status.

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques: Plasmid Preparation, Sampling, Mutagenesis

    To explore alternative classifiers for G2019S carriers and healthy controls, here we applied the same method as described for the 18-feature G2019S phospho-/protein signature, and considered exclusively cross-group differential proteins but not phospho-sites. ( a ) 17-protein G2019S best classifier found in G2019S carriers, symptomatic and asymptomatic, and controls. ( b ) Relative contribution of features from the 17-protein G2019S classifier shown on the upper bar plot; Metascape gene ontology enrichment analysis of the 17-feature G2019S signature displayed on lower bar plot. ( c ) Receiver Operating Curve (ROC) analysis of the 17-protein G2019S signature with a balanced accuracy of 0.963 for discriminating G2019S L2PD, G2019S L2NMCs and controls, with an area under the curve (AUC) of 1.00 between G2019S L2PD and controls, and 0.99 between G2019S L2NMCs and controls. ( d ) Principal component analysis (PCA) based on the 17-protein G2019S classifier displaying different subject profiles of G2019S carriers and healthy controls based on LRRK2 mutation and disease status.

    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet: To explore alternative classifiers for G2019S carriers and healthy controls, here we applied the same method as described for the 18-feature G2019S phospho-/protein signature, and considered exclusively cross-group differential proteins but not phospho-sites. ( a ) 17-protein G2019S best classifier found in G2019S carriers, symptomatic and asymptomatic, and controls. ( b ) Relative contribution of features from the 17-protein G2019S classifier shown on the upper bar plot; Metascape gene ontology enrichment analysis of the 17-feature G2019S signature displayed on lower bar plot. ( c ) Receiver Operating Curve (ROC) analysis of the 17-protein G2019S signature with a balanced accuracy of 0.963 for discriminating G2019S L2PD, G2019S L2NMCs and controls, with an area under the curve (AUC) of 1.00 between G2019S L2PD and controls, and 0.99 between G2019S L2NMCs and controls. ( d ) Principal component analysis (PCA) based on the 17-protein G2019S classifier displaying different subject profiles of G2019S carriers and healthy controls based on LRRK2 mutation and disease status.

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques: Mutagenesis

    Correlation analysis of differential proteins and phospho-proteins (log2FC>|0.6|, adj. P<0.05) and UPDRS-III motor scores from L2PD patients and healthy controls with statistical significance set at a Spearman’s correlation coefficient Rho>|0.5| and an FDR multiple-testing adj. P<0.05. ( a ) Correlation plots between differential proteins in G2019S L2PD vs controls on the left, and R1441G L2PD vs controls on the right, showing differential hits correlating with UPDRS-III in red. ( b ) Scatter plot of 10 hits from the 18-feature G2019S phospho-/protein signature correlating with UPDRS-III in G2019S L2PD patients represented as orange dots and healthy controls as blue dots, including PDCD6, ARHGAP45, ATIC, SCLY, PSMC5, NDUFB8, LAMP1, HSD17B10, RAB9A, and pSer106 RAB12.

    Journal: medRxiv

    Article Title: In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s

    doi: 10.1101/2024.05.04.24306824

    Figure Lengend Snippet: Correlation analysis of differential proteins and phospho-proteins (log2FC>|0.6|, adj. P<0.05) and UPDRS-III motor scores from L2PD patients and healthy controls with statistical significance set at a Spearman’s correlation coefficient Rho>|0.5| and an FDR multiple-testing adj. P<0.05. ( a ) Correlation plots between differential proteins in G2019S L2PD vs controls on the left, and R1441G L2PD vs controls on the right, showing differential hits correlating with UPDRS-III in red. ( b ) Scatter plot of 10 hits from the 18-feature G2019S phospho-/protein signature correlating with UPDRS-III in G2019S L2PD patients represented as orange dots and healthy controls as blue dots, including PDCD6, ARHGAP45, ATIC, SCLY, PSMC5, NDUFB8, LAMP1, HSD17B10, RAB9A, and pSer106 RAB12.

    Article Snippet: We genotyped the most common LRRK2 mutations in our population using Taqman SNP assays-on-demand for LRRK2 G2019S (Thermo Fisher Sci., #C-63498123-10) and a commercial TaqMan assay for LRRK2 R1441G on a Step One Plus Real-time PCR System (Life Tech.

    Techniques:

    ( A and B ) A549 cells were transfected with siRNA targeting LRRK2 and its Rab substrates, lysed 3 days after transfection, and the levels of pT73 Rab10 and LRRK2 were quantified using Meso Scale Discovery (MSD)-based analysis. The MSD signal was normalized to the protein concentration, and data are shown on a log 2 scale as the mean ± SEM; n=3 independent experiments, and statistical significance was determined using one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test. ( C ) RAB12 mRNA levels were quantified using RT-qPCR-based analysis and normalized to GAPDH following transfection with siRNAs targeting a scramble sequence or RAB12. Data are shown as the mean ± SEM; n=3 independent experiments, and statistical significance was determined using paired t-test. ( D ) The levels of pT73 Rab10, Rab10, Rab12, LRRK2, and Rab8a following siRNA-mediated knockdown of LRRK2 and its Rab substrates were assessed in A549 cells by western blot analysis. Shown is a representative immunoblot with GAPDH as a loading control. ( E and F ) The immunoblot signals from multiple experiments were quantified, and the Rab12 and Rab10 signal was normalized to GAPDH, normalized to the median within each batch and expressed as a fold change compared to the scramble control; data are shown as the mean ± SEM; n=3 independent experiments. Statistical significance was determined using unpaired t-test. *p<0.05, **p<0.01, ****p<0.0001. Figure 1—source data 1. Raw data files for western blots. Figure 1—source data 2. Annotated western blots.

    Journal: eLife

    Article Title: Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes

    doi: 10.7554/eLife.87255

    Figure Lengend Snippet: ( A and B ) A549 cells were transfected with siRNA targeting LRRK2 and its Rab substrates, lysed 3 days after transfection, and the levels of pT73 Rab10 and LRRK2 were quantified using Meso Scale Discovery (MSD)-based analysis. The MSD signal was normalized to the protein concentration, and data are shown on a log 2 scale as the mean ± SEM; n=3 independent experiments, and statistical significance was determined using one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test. ( C ) RAB12 mRNA levels were quantified using RT-qPCR-based analysis and normalized to GAPDH following transfection with siRNAs targeting a scramble sequence or RAB12. Data are shown as the mean ± SEM; n=3 independent experiments, and statistical significance was determined using paired t-test. ( D ) The levels of pT73 Rab10, Rab10, Rab12, LRRK2, and Rab8a following siRNA-mediated knockdown of LRRK2 and its Rab substrates were assessed in A549 cells by western blot analysis. Shown is a representative immunoblot with GAPDH as a loading control. ( E and F ) The immunoblot signals from multiple experiments were quantified, and the Rab12 and Rab10 signal was normalized to GAPDH, normalized to the median within each batch and expressed as a fold change compared to the scramble control; data are shown as the mean ± SEM; n=3 independent experiments. Statistical significance was determined using unpaired t-test. *p<0.05, **p<0.01, ****p<0.0001. Figure 1—source data 1. Raw data files for western blots. Figure 1—source data 2. Annotated western blots.

    Article Snippet: Cell line ( H. sapiens ) , LRRK2 R1441G KI A549 cells , Denali , , .

    Techniques: Transfection, Protein Concentration, Comparison, Quantitative RT-PCR, Sequencing, Knockdown, Western Blot, Control

    ( A ) A549 cells were transfected with siRNA targeting LRRK2 and its Rab substrates, lysed 3 days after transfection, and knockdown was confirmed by qPCR-based analysis. The expression of each gene assessed was normalized to GAPDH expression, and then normalized to the expression observed with a scramble siRNA sequence. n=3 independent experiments. Data are shown as the mean ± SEM, with p values based on paired t-test. ( B ) A549 cells were transfected with a scramble siRNA sequence or siRNA targeting RAB12, and the levels of pT73 Rab10, Rab10, and LRRK2 were assessed by western blot analysis. GAPDH was used as a loading control. ( C ) Wildtype (WT) and RAB29 KO A549 cells were treated with L-leucyl-L-leucine methyl ester (LLOMe) (1 mM) for 2 hr, and the levels of pT73 Rab10 were assessed by meso scale discovery (MSD)-based analysis. The MSD signal was normalized for protein input, then normalized to the median within each batch and expressed as a fold change compared to WT untreated A549 cells; data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using one-way analysis of variance (ANOVA) with Sidak’s multiple comparison test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Figure 1—figure supplement 1—source data 1. Raw data files for western blots. Figure 1—figure supplement 1—source data 2. Annotated western blots.

    Journal: eLife

    Article Title: Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes

    doi: 10.7554/eLife.87255

    Figure Lengend Snippet: ( A ) A549 cells were transfected with siRNA targeting LRRK2 and its Rab substrates, lysed 3 days after transfection, and knockdown was confirmed by qPCR-based analysis. The expression of each gene assessed was normalized to GAPDH expression, and then normalized to the expression observed with a scramble siRNA sequence. n=3 independent experiments. Data are shown as the mean ± SEM, with p values based on paired t-test. ( B ) A549 cells were transfected with a scramble siRNA sequence or siRNA targeting RAB12, and the levels of pT73 Rab10, Rab10, and LRRK2 were assessed by western blot analysis. GAPDH was used as a loading control. ( C ) Wildtype (WT) and RAB29 KO A549 cells were treated with L-leucyl-L-leucine methyl ester (LLOMe) (1 mM) for 2 hr, and the levels of pT73 Rab10 were assessed by meso scale discovery (MSD)-based analysis. The MSD signal was normalized for protein input, then normalized to the median within each batch and expressed as a fold change compared to WT untreated A549 cells; data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using one-way analysis of variance (ANOVA) with Sidak’s multiple comparison test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Figure 1—figure supplement 1—source data 1. Raw data files for western blots. Figure 1—figure supplement 1—source data 2. Annotated western blots.

    Article Snippet: Cell line ( H. sapiens ) , LRRK2 R1441G KI A549 cells , Denali , , .

    Techniques: Transfection, Knockdown, Expressing, Sequencing, Western Blot, Control, Comparison

    ( A ) The levels of Rab12, pS106 Rab12, pT73 Rab10, and Rab10 were assessed in wildtype (WT), RAB12 KO, and LRRK2 KO A549 cells by western blot analysis. Shown is a representative immunoblot with GAPDH as a loading control. ( B ) The levels of pT73 Rab10 were measured using a Meso Scale Discovery (MSD)-based assay. The MSD signal was normalized for protein input and expressed as a fold change compared to WT A549 cells; data are shown as the mean ± SEM; n=4 independent experiments, and statistical significance was determined using one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test. ( C ) Immunoblot signals from multiple experiments were quantified, and the Rab10 signal was normalized to GAPDH and expressed as a fold change compared to WT A549 cells. Data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using one-way ANOVA with Dunnett’s multiple comparison test. ( D–F ) RAB12 KO A549 cells with doxycycline-inducible expression of WT RAB12 or a phospho-deficient variant of RAB12 (S106A) were treated with increasing concentrations of doxycycline for 3 days, and the levels of Rab12, pS106 Rab12, pT73 Rab10, and LRRK2 were measured. ( D ) A representative immunoblot is shown assessing Rab12 and pS106 Rab12 protein levels following doxycycline-induced expression of WT or RAB12 S106A, and GAPDH was used as a loading control. ( E and F ) The levels of pT73 Rab10 and LRRK2 were measured using MSD-based assays. MSD signals were normalized for protein concentration, and data were then normalized to the median within each batch and to the signals from the control group (RAB12 KO cells with inducible expression of WT Rab12 without doxycycline treatment). Data are shown as mean ± SEM; n=3–4 independent experiments, and statistical significance was determined using unpaired t-test on log transformed data. ( G ) The impact of Rab12 knockdown was measured in WT, LRRK2 R1441G KI, and VPS35 D620N KI A549 cells. Cells were transfected with siRNA targeting RAB12, and pT73 Rab10 levels were measured by MSD-based analysis 3 days after transfection. The MSD signal was normalized for protein input and then normalized to the median within each batch and is expressed as a fold change compared to WT A549 cells transfected with scramble siRNA. Data are shown as the mean ± SEM; n=5 independent experiments. Statistical significance was determined using one-way ANOVA with Tukey’s multiple comparison test on log transformed data. ( H ) WT, RAB12 KO, and LRRK2 KO A549 cells were treated with vehicle or L-leucyl-L-leucine methyl ester (LLOMe) (1 mM) for 2 hr, and the impact of LLOMe treatment on pT73 Rab10 levels was measured by MSD-based analysis. The MSD signal was normalized for protein input and is expressed as a fold change compared to WT A549 cells treated with vehicle. Data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using two-way ANOVA with Sidak’s multiple comparison test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Figure 2—source data 1. Raw data files for western blot. Figure 2—source data 2. Annotated western blots.

    Journal: eLife

    Article Title: Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes

    doi: 10.7554/eLife.87255

    Figure Lengend Snippet: ( A ) The levels of Rab12, pS106 Rab12, pT73 Rab10, and Rab10 were assessed in wildtype (WT), RAB12 KO, and LRRK2 KO A549 cells by western blot analysis. Shown is a representative immunoblot with GAPDH as a loading control. ( B ) The levels of pT73 Rab10 were measured using a Meso Scale Discovery (MSD)-based assay. The MSD signal was normalized for protein input and expressed as a fold change compared to WT A549 cells; data are shown as the mean ± SEM; n=4 independent experiments, and statistical significance was determined using one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test. ( C ) Immunoblot signals from multiple experiments were quantified, and the Rab10 signal was normalized to GAPDH and expressed as a fold change compared to WT A549 cells. Data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using one-way ANOVA with Dunnett’s multiple comparison test. ( D–F ) RAB12 KO A549 cells with doxycycline-inducible expression of WT RAB12 or a phospho-deficient variant of RAB12 (S106A) were treated with increasing concentrations of doxycycline for 3 days, and the levels of Rab12, pS106 Rab12, pT73 Rab10, and LRRK2 were measured. ( D ) A representative immunoblot is shown assessing Rab12 and pS106 Rab12 protein levels following doxycycline-induced expression of WT or RAB12 S106A, and GAPDH was used as a loading control. ( E and F ) The levels of pT73 Rab10 and LRRK2 were measured using MSD-based assays. MSD signals were normalized for protein concentration, and data were then normalized to the median within each batch and to the signals from the control group (RAB12 KO cells with inducible expression of WT Rab12 without doxycycline treatment). Data are shown as mean ± SEM; n=3–4 independent experiments, and statistical significance was determined using unpaired t-test on log transformed data. ( G ) The impact of Rab12 knockdown was measured in WT, LRRK2 R1441G KI, and VPS35 D620N KI A549 cells. Cells were transfected with siRNA targeting RAB12, and pT73 Rab10 levels were measured by MSD-based analysis 3 days after transfection. The MSD signal was normalized for protein input and then normalized to the median within each batch and is expressed as a fold change compared to WT A549 cells transfected with scramble siRNA. Data are shown as the mean ± SEM; n=5 independent experiments. Statistical significance was determined using one-way ANOVA with Tukey’s multiple comparison test on log transformed data. ( H ) WT, RAB12 KO, and LRRK2 KO A549 cells were treated with vehicle or L-leucyl-L-leucine methyl ester (LLOMe) (1 mM) for 2 hr, and the impact of LLOMe treatment on pT73 Rab10 levels was measured by MSD-based analysis. The MSD signal was normalized for protein input and is expressed as a fold change compared to WT A549 cells treated with vehicle. Data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using two-way ANOVA with Sidak’s multiple comparison test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Figure 2—source data 1. Raw data files for western blot. Figure 2—source data 2. Annotated western blots.

    Article Snippet: Cell line ( H. sapiens ) , LRRK2 R1441G KI A549 cells , Denali , , .

    Techniques: Western Blot, Control, Comparison, Expressing, Variant Assay, Protein Concentration, Transformation Assay, Knockdown, Transfection

    ( A ) The levels of Rab12 were measured in cell lysate from wildtype (WT) or three clones of RAB12 KO A549 cells by western blot analysis. The Rab12 signal was quantified and normalized to the GAPDH signal and expressed as a fold change compared to WT cells. Data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test. ( B ) The levels of pT73 Rab10 were measured in cell lysates from WT, three clones of RAB12 KO A549 cells, or LRRK2 KO A549 cells by meso scale discovery (MSD)-based analysis and were normalized to the levels of Rab10 (measured by western blot analysis). Data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using one-way ANOVA with Dunnett’s multiple comparisons test. ( C–G ) The levels of pS106 Rab12, Rab12, pT73 Rab10, and Rab10 were measured in cell lysates from WT, three clones of RAB12 S106A KI A549, or RAB12 KO cells by western blot analysis, and GAPDH was used as a loading control. The pS106 Rab12 signal ( C ), Rab12 signal ( D ), pT73 Rab10 signal ( E ), and Rab10 signal ( F ) were measured and normalized to the GAPDH signal and expressed as a fold change compared to WT cells. pT73 Rab10 levels (measured by MSD-based assay) were normalized to total Rab10 levels (measured by western blot) and expressed as a fold change compared to WT cells ( G ). Data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using one-way ANOVA with Dunnett’s multiple comparison test. ( H ) Total LRRK2 levels were reduced in LRRK2 R1441G cells compared to WT cells. LRRK2 levels were measured in cell lysates from WT and LRRK2 R1441G KI A549 cells treated with scramble siRNA or siRNA against RAB12 by MSD-based analysis and normalized for protein input. Data are shown as the mean ± SEM; n=5 independent experiments. **p<0.01, ***p<0.001, ****p<0.0001. Figure 2—figure supplement 1—source data 1. Raw data files for western blot. Figure 2—figure supplement 1—source data 2. Annotated western blots.

    Journal: eLife

    Article Title: Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes

    doi: 10.7554/eLife.87255

    Figure Lengend Snippet: ( A ) The levels of Rab12 were measured in cell lysate from wildtype (WT) or three clones of RAB12 KO A549 cells by western blot analysis. The Rab12 signal was quantified and normalized to the GAPDH signal and expressed as a fold change compared to WT cells. Data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test. ( B ) The levels of pT73 Rab10 were measured in cell lysates from WT, three clones of RAB12 KO A549 cells, or LRRK2 KO A549 cells by meso scale discovery (MSD)-based analysis and were normalized to the levels of Rab10 (measured by western blot analysis). Data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using one-way ANOVA with Dunnett’s multiple comparisons test. ( C–G ) The levels of pS106 Rab12, Rab12, pT73 Rab10, and Rab10 were measured in cell lysates from WT, three clones of RAB12 S106A KI A549, or RAB12 KO cells by western blot analysis, and GAPDH was used as a loading control. The pS106 Rab12 signal ( C ), Rab12 signal ( D ), pT73 Rab10 signal ( E ), and Rab10 signal ( F ) were measured and normalized to the GAPDH signal and expressed as a fold change compared to WT cells. pT73 Rab10 levels (measured by MSD-based assay) were normalized to total Rab10 levels (measured by western blot) and expressed as a fold change compared to WT cells ( G ). Data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using one-way ANOVA with Dunnett’s multiple comparison test. ( H ) Total LRRK2 levels were reduced in LRRK2 R1441G cells compared to WT cells. LRRK2 levels were measured in cell lysates from WT and LRRK2 R1441G KI A549 cells treated with scramble siRNA or siRNA against RAB12 by MSD-based analysis and normalized for protein input. Data are shown as the mean ± SEM; n=5 independent experiments. **p<0.01, ***p<0.001, ****p<0.0001. Figure 2—figure supplement 1—source data 1. Raw data files for western blot. Figure 2—figure supplement 1—source data 2. Annotated western blots.

    Article Snippet: Cell line ( H. sapiens ) , LRRK2 R1441G KI A549 cells , Denali , , .

    Techniques: Clone Assay, Western Blot, Control, Comparison

    ( A ) Lysosomes were isolated from wildtype (WT) and RAB12 KO A549 cells treated with vehicle or L-leucyl-L-leucine methyl ester (LLOMe) (1 mM) for 2 hr. The levels of pT73 Rab10, total Rab10, pS106 Rab12, galectin-3 (Gal3), lysosomal-associated membrane protein 1 (LAMP1), and HA were assessed by western blot analysis, and shown is a representative immunoblot. Fluorescence signals of immunoblots from multiple experiments were quantified. The pT73 Rab10 signal was normalized to the HA signal, then was normalized to the median within each experimental replicate and expressed as a fold change compared to lysosomes isolated from WT A549 cells treated with vehicle. n=6 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test. ( B ) WT, RAB12 KO, and LRRK2 KO A549 cells were treated with vehicle or LLOMe (1 mM) for 2 hr, and the signals of pT73 Rab10 and LAMP1 were assessed by immunostaining. Scale bar, 20 μm. pT73 Rab10 (shown in magenta) and LAMP1 (shown in cyan) double positive puncta (i.e. overlap of magenta and cyan and shown in white) were quantified per cell from n=3 independent experiments. Data are shown as the mean ± SEM with and statistical significance was determined using two-way ANOVA with Sidak’s multiple comparison test. ( C ) Lysosomal Rab12 levels were assessed by western blot analysis from lysosomes isolated from WT and RAB12 KO A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr. The Rab12 signals were normalized to the HA signals, then were normalized to the median within each experimental replicate and expressed as a fold change compared to lysosomes isolated from WT A549 cells treated with vehicle. n=6 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using one-way ANOVA with Tukey’s multiple comparison test. ( D ) HEK293T cells expressing mCherry-Rab12 were treated with vehicle or LLOMe (1 mM) for 2 hr, fixed, and stained using an antibody against LAMP1. Colocalization of Rab12 and LAMP1 was assessed by measuring the Pearson’s correlation coefficient between mCherry-Rab12 (shown in magenta) and LAMP1 (shown in cyan); nocodazole (25 μΜ for 2 hr) treatment was included as a control to confirm colocalization. Scale bar, 10 μm. n=3 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using repeated measures one-way ANOVA with Sidak’s multiple comparison test. ( E ) WT and LRRK2 KO A549 cells transiently expressing mCherry-Rab12 were treated with vehicle or LLOMe (1 mM) for 2 hr, and the LAMP1 levels were assessed by immunostaining. Scale bar, 20 μm. The intensity of mCherry-Rab12 signals (shown in magenta) in LAMP1 (shown in cyan)-positive region were quantified per cell from mCherry-Rab12 expressing cells (n=20 cells per condition, with cellular intensity between 2000 and 5000 fl. units) and averaged across wells (~4–6 wells per condition). n=3 independent experiments. The Rab12 signal was normalized to the median within each experimental replicate, and then expressed as a fold change compared to WT cells treated with vehicle. Data are shown as the mean ± SEM, and statistical significance was determined using one-way ANOVA with Sidak’s multiple comparison test. ( F ) HEK293T cells stably expressing eGFP-LRRK2 were transfected with mCherry-Rab12 and treated with LLOMe (1 mM) for 2 hr. Colocalization of mCherry-Rab12 (shown in magenta) and eGFP-LRRK2 (shown in cyan) was assessed by measuring the Pearson’s correlation coefficient in LLOMe-responding cells (n=10 cells per condition); nocodazole (25 μΜ) treatment was included to confirm colocalization. Scale bar, 10 μm. n=3 independent experiments. ( G ) HEK293T cells stably expressing eGFP-LRRK2 were treated with vehicle or LLOMe (1 mM) for 2 hr, fixed, and stained using an antibody against LAMP1. Colocalization of LRRK2 and LAMP1 was assessed by measuring the Pearson’s correlation coefficient between eGFP-LRRK2 (shown in cyan) and LAMP1 (shown in magenta); nocodazole (25 μΜ) treatment was included to confirm colocalization. Scale bar, 10 μm. n=3 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using repeated measures one-way ANOVA with Sidak’s multiple comparison test. **p<0.01, ***p<0.001, and ****p<0.0001. Figure 3—source data 1. Raw data files for western blot. Figure 3—source data 2. Annotated western blots.

    Journal: eLife

    Article Title: Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes

    doi: 10.7554/eLife.87255

    Figure Lengend Snippet: ( A ) Lysosomes were isolated from wildtype (WT) and RAB12 KO A549 cells treated with vehicle or L-leucyl-L-leucine methyl ester (LLOMe) (1 mM) for 2 hr. The levels of pT73 Rab10, total Rab10, pS106 Rab12, galectin-3 (Gal3), lysosomal-associated membrane protein 1 (LAMP1), and HA were assessed by western blot analysis, and shown is a representative immunoblot. Fluorescence signals of immunoblots from multiple experiments were quantified. The pT73 Rab10 signal was normalized to the HA signal, then was normalized to the median within each experimental replicate and expressed as a fold change compared to lysosomes isolated from WT A549 cells treated with vehicle. n=6 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test. ( B ) WT, RAB12 KO, and LRRK2 KO A549 cells were treated with vehicle or LLOMe (1 mM) for 2 hr, and the signals of pT73 Rab10 and LAMP1 were assessed by immunostaining. Scale bar, 20 μm. pT73 Rab10 (shown in magenta) and LAMP1 (shown in cyan) double positive puncta (i.e. overlap of magenta and cyan and shown in white) were quantified per cell from n=3 independent experiments. Data are shown as the mean ± SEM with and statistical significance was determined using two-way ANOVA with Sidak’s multiple comparison test. ( C ) Lysosomal Rab12 levels were assessed by western blot analysis from lysosomes isolated from WT and RAB12 KO A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr. The Rab12 signals were normalized to the HA signals, then were normalized to the median within each experimental replicate and expressed as a fold change compared to lysosomes isolated from WT A549 cells treated with vehicle. n=6 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using one-way ANOVA with Tukey’s multiple comparison test. ( D ) HEK293T cells expressing mCherry-Rab12 were treated with vehicle or LLOMe (1 mM) for 2 hr, fixed, and stained using an antibody against LAMP1. Colocalization of Rab12 and LAMP1 was assessed by measuring the Pearson’s correlation coefficient between mCherry-Rab12 (shown in magenta) and LAMP1 (shown in cyan); nocodazole (25 μΜ for 2 hr) treatment was included as a control to confirm colocalization. Scale bar, 10 μm. n=3 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using repeated measures one-way ANOVA with Sidak’s multiple comparison test. ( E ) WT and LRRK2 KO A549 cells transiently expressing mCherry-Rab12 were treated with vehicle or LLOMe (1 mM) for 2 hr, and the LAMP1 levels were assessed by immunostaining. Scale bar, 20 μm. The intensity of mCherry-Rab12 signals (shown in magenta) in LAMP1 (shown in cyan)-positive region were quantified per cell from mCherry-Rab12 expressing cells (n=20 cells per condition, with cellular intensity between 2000 and 5000 fl. units) and averaged across wells (~4–6 wells per condition). n=3 independent experiments. The Rab12 signal was normalized to the median within each experimental replicate, and then expressed as a fold change compared to WT cells treated with vehicle. Data are shown as the mean ± SEM, and statistical significance was determined using one-way ANOVA with Sidak’s multiple comparison test. ( F ) HEK293T cells stably expressing eGFP-LRRK2 were transfected with mCherry-Rab12 and treated with LLOMe (1 mM) for 2 hr. Colocalization of mCherry-Rab12 (shown in magenta) and eGFP-LRRK2 (shown in cyan) was assessed by measuring the Pearson’s correlation coefficient in LLOMe-responding cells (n=10 cells per condition); nocodazole (25 μΜ) treatment was included to confirm colocalization. Scale bar, 10 μm. n=3 independent experiments. ( G ) HEK293T cells stably expressing eGFP-LRRK2 were treated with vehicle or LLOMe (1 mM) for 2 hr, fixed, and stained using an antibody against LAMP1. Colocalization of LRRK2 and LAMP1 was assessed by measuring the Pearson’s correlation coefficient between eGFP-LRRK2 (shown in cyan) and LAMP1 (shown in magenta); nocodazole (25 μΜ) treatment was included to confirm colocalization. Scale bar, 10 μm. n=3 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using repeated measures one-way ANOVA with Sidak’s multiple comparison test. **p<0.01, ***p<0.001, and ****p<0.0001. Figure 3—source data 1. Raw data files for western blot. Figure 3—source data 2. Annotated western blots.

    Article Snippet: Cell line ( H. sapiens ) , LRRK2 R1441G KI A549 cells , Denali , , .

    Techniques: Isolation, Membrane, Western Blot, Fluorescence, Comparison, Immunostaining, Expressing, Staining, Control, Stable Transfection, Transfection

    ( A ) Wildtype (WT) A549 cells stably expressing TMEM192-3x-HA were treated with vehicle or L-leucyl-L-leucine methyl ester (LLOMe) (1 mM) for 2 hr, and HA (to detect TMEM192-3x-HA) and lysosomal-associated membrane protein 1 (LAMP1) signals were assessed by immunostaining. Scale bar, 20 μm. Percentage of HA (shown in magenta) and LAMP1 (shown in cyan) double positive puncta (i.e. overlap of magenta and cyan and shown in white) over total HA puncta were quantified per cell from n=3 independent experiments. Data are shown as the mean ± SEM. ( B ) Representative immunoblot from analysis of isolated lysosomes (IP: HA) and the post-nuclear supernatant (PNS) fraction (corresponding to ) in WT and Rab12 KO A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr. ( C ) Lysosomal Rab10 levels were assessed by western blot analysis from lysosomes isolated from WT and RAB12 KO A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr. Rab10 levels were then normalized to the HA signal, then were normalized to the median within each experimental replicate and expressed as a fold change compared to lysosomes isolated from WT cells treated with vehicle (corresponding to ); n=6 independent experiments. ( D ) pT73 Rab10 signals were assessed by immunostaining of WT, RAB12 KO, and LRRK2 KO A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr (corresponding to ). The sum intensity of puncta per cell was quantified from n=3 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using two-way analysis of variance (ANOVA) with Sidak’s multiple comparison test. ( E ) Percentage of pT73 Rab10 puncta colocalized with LAMP1 were quantified from WT A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr. Data are shown as the mean ± SEM, n=3 independent experiments. ( F ) Representative immunoblot from analysis of isolated lysosomes (IP: HA) and PNS (corresponding to ) from WT and Rab12 KO A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr. ( G ) HEK293T cells transiently expressing mCherry-Rab12 were treated with vehicle or LLOMe (1 mM) for 2 hr, fixed, and stained using an antibody against GM130 as a marker of the Golgi. Colocalization of Rab12 and GM130 was measured using the Pearson’s correlation coefficient between mCherry-Rab12 (shown in magenta) and GM130 (shown in yellow); nocodazole (25 μΜ) treatment was included to confirm colocalization. Scale bar, 10 μm. n=3 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using repeated measures one-way ANOVA with Sidak’s multiple comparison test. Figure 3—figure supplement 1—source data 1. Raw data files for western blot. Figure 3—figure supplement 1—source data 2. Annotated western blots.

    Journal: eLife

    Article Title: Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes

    doi: 10.7554/eLife.87255

    Figure Lengend Snippet: ( A ) Wildtype (WT) A549 cells stably expressing TMEM192-3x-HA were treated with vehicle or L-leucyl-L-leucine methyl ester (LLOMe) (1 mM) for 2 hr, and HA (to detect TMEM192-3x-HA) and lysosomal-associated membrane protein 1 (LAMP1) signals were assessed by immunostaining. Scale bar, 20 μm. Percentage of HA (shown in magenta) and LAMP1 (shown in cyan) double positive puncta (i.e. overlap of magenta and cyan and shown in white) over total HA puncta were quantified per cell from n=3 independent experiments. Data are shown as the mean ± SEM. ( B ) Representative immunoblot from analysis of isolated lysosomes (IP: HA) and the post-nuclear supernatant (PNS) fraction (corresponding to ) in WT and Rab12 KO A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr. ( C ) Lysosomal Rab10 levels were assessed by western blot analysis from lysosomes isolated from WT and RAB12 KO A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr. Rab10 levels were then normalized to the HA signal, then were normalized to the median within each experimental replicate and expressed as a fold change compared to lysosomes isolated from WT cells treated with vehicle (corresponding to ); n=6 independent experiments. ( D ) pT73 Rab10 signals were assessed by immunostaining of WT, RAB12 KO, and LRRK2 KO A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr (corresponding to ). The sum intensity of puncta per cell was quantified from n=3 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using two-way analysis of variance (ANOVA) with Sidak’s multiple comparison test. ( E ) Percentage of pT73 Rab10 puncta colocalized with LAMP1 were quantified from WT A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr. Data are shown as the mean ± SEM, n=3 independent experiments. ( F ) Representative immunoblot from analysis of isolated lysosomes (IP: HA) and PNS (corresponding to ) from WT and Rab12 KO A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr. ( G ) HEK293T cells transiently expressing mCherry-Rab12 were treated with vehicle or LLOMe (1 mM) for 2 hr, fixed, and stained using an antibody against GM130 as a marker of the Golgi. Colocalization of Rab12 and GM130 was measured using the Pearson’s correlation coefficient between mCherry-Rab12 (shown in magenta) and GM130 (shown in yellow); nocodazole (25 μΜ) treatment was included to confirm colocalization. Scale bar, 10 μm. n=3 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using repeated measures one-way ANOVA with Sidak’s multiple comparison test. Figure 3—figure supplement 1—source data 1. Raw data files for western blot. Figure 3—figure supplement 1—source data 2. Annotated western blots.

    Article Snippet: Cell line ( H. sapiens ) , LRRK2 R1441G KI A549 cells , Denali , , .

    Techniques: Stable Transfection, Expressing, Membrane, Immunostaining, Western Blot, Isolation, Comparison, Staining, Marker

    ( A ) Lysosomal Rab12 levels were assessed by western blot analysis from lysosomes isolated from wildtype (WT), LRRK2 R1441G, and LRRK2 KO A549 cells treated with vehicle or L-leucyl-L-leucine methyl ester (LLOMe) (1 mM) for 2 hr. The Rab12 signals were normalized to the median within each experimental replicate and expressed as a fold change compared to lysosomes isolated from WT A549 cells treated with vehicle. n=3 independent experiments. Data are shown as the mean ± SEM and statistical significance was determined using one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test. ( B ) Representative live-cell images show the recruitment of Rab12 and LRRK2 upon LLOMe (1 mM) treatment. HEK293T cells were transfected with mCherry-Rab12 and eGFP-LRRK2, and images were acquired every 10 min. Scale bar, 5 μm. ( C–E ) Normalized mean intensity of mCherry-Rab12 ( C ) and eGFP-LRRK2 ( D ) were quantified over time in segmented cells (n=24 cells). ( E ) Pearson’s correlation coefficient (PCC) between normalized eGFP-LRRK2 and mCherry-Rab12 were quantified over time in segmented cells (n=24 cells); n=3 experiments. Data are shown as mean ± SEM. ( F ) HEK293T cells stably expressing eGFP-LRRK2 were treated with vehicle or LLOMe (1 mM) for 2 hr, fixed, and stained using an antibody against the Golgi marker GM130. Colocalization of LRRK2 and GM130 was assessed by measuring the PCC between eGFP-LRRK2 (shown in cyan) and GM130 (shown in yellow); nocodazole (25 μΜ) treatment was included to confirm colocalization. Scale bar, 10 μm; n=3 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using repeated measures one-way ANOVA with Sidak’s multiple comparison test. ( G ) The percentage of total Rab12 and LRRK2 localized to lysosomes was assessed using western blot analysis of lysosomes isolated from A549 cells treated with vehicle or LLOMe and estimated based on the signals of Rab12 and LRRK2 in the lysosomal fraction normalized to the signals in the post-nuclear supernatant (PNS) fraction. Our analysis of total HA recovery from isolated lysosomes confirmed that not all of the HA-labeled lysosomes were captured, suggesting that the estimated lysosomal LRRK2 and Rab12 levels using this method are likely an underestimate; n=4–6 experiments. Data are shown as the mean ± SEM, and statistical significance was determined using unpaired t-test. ( H ) The percentage of Rab12 and LRRK2 localized to lysosomes was assessed using imaging-based analysis. HEK293T cells transfected with either mCherry-Rab12 or eGFP-LRRK2 were treated with vehicle or LLOMe, fixed, and stained using an antibody against lysosomal-associated membrane protein 1 (LAMP1). The percentage of Rab12 and LRRK2 localized to lysosomes was quantified using the sum intensity of Rab12 or LRRK2 in the LAMP1-positive region normalized to the sum intensity of Rab12 or LRRK2 in the whole cell region. n=3–4 experiments. The data were normalized to the median within each experiment. Data are shown as the mean ± SEM, and statistical significance was determined using unpaired t-test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

    Journal: eLife

    Article Title: Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes

    doi: 10.7554/eLife.87255

    Figure Lengend Snippet: ( A ) Lysosomal Rab12 levels were assessed by western blot analysis from lysosomes isolated from wildtype (WT), LRRK2 R1441G, and LRRK2 KO A549 cells treated with vehicle or L-leucyl-L-leucine methyl ester (LLOMe) (1 mM) for 2 hr. The Rab12 signals were normalized to the median within each experimental replicate and expressed as a fold change compared to lysosomes isolated from WT A549 cells treated with vehicle. n=3 independent experiments. Data are shown as the mean ± SEM and statistical significance was determined using one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test. ( B ) Representative live-cell images show the recruitment of Rab12 and LRRK2 upon LLOMe (1 mM) treatment. HEK293T cells were transfected with mCherry-Rab12 and eGFP-LRRK2, and images were acquired every 10 min. Scale bar, 5 μm. ( C–E ) Normalized mean intensity of mCherry-Rab12 ( C ) and eGFP-LRRK2 ( D ) were quantified over time in segmented cells (n=24 cells). ( E ) Pearson’s correlation coefficient (PCC) between normalized eGFP-LRRK2 and mCherry-Rab12 were quantified over time in segmented cells (n=24 cells); n=3 experiments. Data are shown as mean ± SEM. ( F ) HEK293T cells stably expressing eGFP-LRRK2 were treated with vehicle or LLOMe (1 mM) for 2 hr, fixed, and stained using an antibody against the Golgi marker GM130. Colocalization of LRRK2 and GM130 was assessed by measuring the PCC between eGFP-LRRK2 (shown in cyan) and GM130 (shown in yellow); nocodazole (25 μΜ) treatment was included to confirm colocalization. Scale bar, 10 μm; n=3 independent experiments. Data are shown as the mean ± SEM, and statistical significance was determined using repeated measures one-way ANOVA with Sidak’s multiple comparison test. ( G ) The percentage of total Rab12 and LRRK2 localized to lysosomes was assessed using western blot analysis of lysosomes isolated from A549 cells treated with vehicle or LLOMe and estimated based on the signals of Rab12 and LRRK2 in the lysosomal fraction normalized to the signals in the post-nuclear supernatant (PNS) fraction. Our analysis of total HA recovery from isolated lysosomes confirmed that not all of the HA-labeled lysosomes were captured, suggesting that the estimated lysosomal LRRK2 and Rab12 levels using this method are likely an underestimate; n=4–6 experiments. Data are shown as the mean ± SEM, and statistical significance was determined using unpaired t-test. ( H ) The percentage of Rab12 and LRRK2 localized to lysosomes was assessed using imaging-based analysis. HEK293T cells transfected with either mCherry-Rab12 or eGFP-LRRK2 were treated with vehicle or LLOMe, fixed, and stained using an antibody against lysosomal-associated membrane protein 1 (LAMP1). The percentage of Rab12 and LRRK2 localized to lysosomes was quantified using the sum intensity of Rab12 or LRRK2 in the LAMP1-positive region normalized to the sum intensity of Rab12 or LRRK2 in the whole cell region. n=3–4 experiments. The data were normalized to the median within each experiment. Data are shown as the mean ± SEM, and statistical significance was determined using unpaired t-test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

    Article Snippet: Cell line ( H. sapiens ) , LRRK2 R1441G KI A549 cells , Denali , , .

    Techniques: Western Blot, Isolation, Comparison, Transfection, Stable Transfection, Expressing, Staining, Marker, Labeling, Imaging, Membrane

    ( A ) To analyze lysosomal LRRK2 levels, lysosomes were isolated from wildtype (WT) and RAB12 KO A549 cells treated with vehicle or L-leucyl-L-leucine methyl ester (LLOMe) (1 mM) for 4 hr. The levels of LRRK2, HA, lysosomal-associated membrane protein 1 (LAMP1), and galectin-3 (Gal3) were assessed by western blot analysis, and shown is a representative immunoblot. Fluorescence signals of immunoblots from multiple experiments were quantified, LRRK2 signal was normalized to the HA signal, then normalized to the median within each experiment, and expressed as a fold change compared to lysosomes isolated from WT A549 cells treated with vehicle. Data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test with a single pooled variance. ( B–C ) To analyze lysosomal pRab10 levels, lysosomes were isolated from WT and LRRK2 R1441G KI ( B ) or VPS35 D620N KI ( C ) A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr, and the levels of pT73 Rab10, Rab10, and LAMP1 were assessed by western blot analysis. Immunoblot signals from multiple experiments were quantified, and the pT73 Rab10 signal was expressed as a fold change compared to lysosomes isolated from WT A549 cells treated with vehicle. Data are shown as the mean ± SEM; n=3 independent experiments ( B ) and n=8 independent experiments ( C ). Statistical significance was determined using unpaired t-test. ( D ) Lysosomes were isolated from WT, LRRK2 R1441G KI, and VPS35 D620N KI A549 cells treated with vehicle or LLOMe (1 mM) for 4 hr. The levels of LRRK2, HA, LAMP1, and Gal3 were assessed by western blot analysis and shown is a representative immunoblot. Fluorescence signals of immunoblots from multiple experiments were quantified, the LRRK2 signal was normalized to the HA signal, then normalized to the median within each experiment, and expressed as a fold change compared to lysosomes isolated from WT A549 cells treated with vehicle. Data are shown as the mean ± SEM; n=7 independent experiments. Statistical significance was determined using one-way ANOVA with Dunnett’s multiple comparison test. *p<0.05, ***p<0.001, ****p<0.0001. ( E ) Model for proposed mechanism by which Rab12 promotes LRRK2 activation. Under steady-state conditions, LRRK2 localizes primarily to the cytoplasm. Lysosomal damage prompts the recruitment of Rab12, and Rab12 regulates the recruitment of LRRK2 to damaged lysosomes. An elevated local concentration of LRRK2 on lysosomes increases the likelihood for interactions with Rab GTPases localized on the lysosomal membrane, promoting LRRK2-dependent phosphorylation of its Rab substrates. Figure 4—source data 1. Raw data files for western blot. Figure 4—source data 2. Annotated western blots.

    Journal: eLife

    Article Title: Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes

    doi: 10.7554/eLife.87255

    Figure Lengend Snippet: ( A ) To analyze lysosomal LRRK2 levels, lysosomes were isolated from wildtype (WT) and RAB12 KO A549 cells treated with vehicle or L-leucyl-L-leucine methyl ester (LLOMe) (1 mM) for 4 hr. The levels of LRRK2, HA, lysosomal-associated membrane protein 1 (LAMP1), and galectin-3 (Gal3) were assessed by western blot analysis, and shown is a representative immunoblot. Fluorescence signals of immunoblots from multiple experiments were quantified, LRRK2 signal was normalized to the HA signal, then normalized to the median within each experiment, and expressed as a fold change compared to lysosomes isolated from WT A549 cells treated with vehicle. Data are shown as the mean ± SEM; n=4 independent experiments. Statistical significance was determined using one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test with a single pooled variance. ( B–C ) To analyze lysosomal pRab10 levels, lysosomes were isolated from WT and LRRK2 R1441G KI ( B ) or VPS35 D620N KI ( C ) A549 cells treated with vehicle or LLOMe (1 mM) for 2 hr, and the levels of pT73 Rab10, Rab10, and LAMP1 were assessed by western blot analysis. Immunoblot signals from multiple experiments were quantified, and the pT73 Rab10 signal was expressed as a fold change compared to lysosomes isolated from WT A549 cells treated with vehicle. Data are shown as the mean ± SEM; n=3 independent experiments ( B ) and n=8 independent experiments ( C ). Statistical significance was determined using unpaired t-test. ( D ) Lysosomes were isolated from WT, LRRK2 R1441G KI, and VPS35 D620N KI A549 cells treated with vehicle or LLOMe (1 mM) for 4 hr. The levels of LRRK2, HA, LAMP1, and Gal3 were assessed by western blot analysis and shown is a representative immunoblot. Fluorescence signals of immunoblots from multiple experiments were quantified, the LRRK2 signal was normalized to the HA signal, then normalized to the median within each experiment, and expressed as a fold change compared to lysosomes isolated from WT A549 cells treated with vehicle. Data are shown as the mean ± SEM; n=7 independent experiments. Statistical significance was determined using one-way ANOVA with Dunnett’s multiple comparison test. *p<0.05, ***p<0.001, ****p<0.0001. ( E ) Model for proposed mechanism by which Rab12 promotes LRRK2 activation. Under steady-state conditions, LRRK2 localizes primarily to the cytoplasm. Lysosomal damage prompts the recruitment of Rab12, and Rab12 regulates the recruitment of LRRK2 to damaged lysosomes. An elevated local concentration of LRRK2 on lysosomes increases the likelihood for interactions with Rab GTPases localized on the lysosomal membrane, promoting LRRK2-dependent phosphorylation of its Rab substrates. Figure 4—source data 1. Raw data files for western blot. Figure 4—source data 2. Annotated western blots.

    Article Snippet: Cell line ( H. sapiens ) , LRRK2 R1441G KI A549 cells , Denali , , .

    Techniques: Isolation, Membrane, Western Blot, Fluorescence, Comparison, Activation Assay, Concentration Assay, Phospho-proteomics

    Journal: eLife

    Article Title: Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes

    doi: 10.7554/eLife.87255

    Figure Lengend Snippet:

    Article Snippet: Cell line ( H. sapiens ) , LRRK2 R1441G KI A549 cells , Denali , , .

    Techniques: Recombinant, Software

    Journal: eLife

    Article Title: Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes

    doi: 10.7554/eLife.87255

    Figure Lengend Snippet:

    Article Snippet: Cell line ( H. sapiens ) , LRRK2 R1441G KI A549 cells , Denali , , .

    Techniques: Sequencing, Control

    Journal: eLife

    Article Title: Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes

    doi: 10.7554/eLife.87255

    Figure Lengend Snippet:

    Article Snippet: Cell line ( H. sapiens ) , LRRK2 R1441G KI A549 cells , Denali , , .

    Techniques: TaqMan Assay

    Journal: eLife

    Article Title: Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes

    doi: 10.7554/eLife.87255

    Figure Lengend Snippet:

    Article Snippet: Cell line ( H. sapiens ) , LRRK2 R1441G KI A549 cells , Denali , , .

    Techniques: Concentration Assay

    ( A–D ) Microscale thermophoresis of Rab12 binding to fluorescently labeled LRRK2 Armadillo domain (residues 1–552) wild type ( A ) or bearing the indicated mutations at Site #1: K439E ( B ) or Site #3: E240R ( C ) and F283A ( D ). Purified Rab12 was serially diluted and then NHS-RED-labeled-LRRK2 Armadillo (final concentration 100 nM) was added. Graphs show mean and SEM from two independent measurements, each the average of two replicate runs. ( E ) Immunoblot of anti-FLAG antibody immunoprecipitation of FLAG-LRRK2 wild type or indicated Site #3 mutants with endogenous or co-expressed HA-Rab12 protein in HEK293 cells. Lysate inputs (1.5%) are shown at left; membranes were probed with anti-FLAG or anti-Rab12 antibodies. ( F ) Quantitation of two independent experiments carried out in duplicate as in ( E ). ****p<0.0001 for LRRK2 E240R and S244R relative to LRRK2 WT by one-way ANOVA. ( G ) Immunoblot analysis of 293T cells transfected with LRRK2 R1441C or K17/18A R1441G and GFP, GFP-Rab8, or GFP-Rab12 for 36 hr; +/-MLi2 (200 nM for 2 hr). ( H ) Quantitation of the fraction of phosphorylated Rab10 from immunoblots as in ( G ) normalized to respective total Rab10 levels, normalized to LRRK2 R1441C+GFP-Rab12. Error bars indicate SEM from two independent experiments; **p=0.003 for LRRK2 R1441C GFP and GFP-Rab12, **p=0.0044 for LRRK2 K17/18A R1441G GFP and GFP-Rab12, ns = 0.6 by Student’s t -test. Figure 8—source data 1. Raw/annotated gels for .

    Journal: eLife

    Article Title: Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson’s disease-linked LRRK2 kinase

    doi: 10.7554/eLife.87098

    Figure Lengend Snippet: ( A–D ) Microscale thermophoresis of Rab12 binding to fluorescently labeled LRRK2 Armadillo domain (residues 1–552) wild type ( A ) or bearing the indicated mutations at Site #1: K439E ( B ) or Site #3: E240R ( C ) and F283A ( D ). Purified Rab12 was serially diluted and then NHS-RED-labeled-LRRK2 Armadillo (final concentration 100 nM) was added. Graphs show mean and SEM from two independent measurements, each the average of two replicate runs. ( E ) Immunoblot of anti-FLAG antibody immunoprecipitation of FLAG-LRRK2 wild type or indicated Site #3 mutants with endogenous or co-expressed HA-Rab12 protein in HEK293 cells. Lysate inputs (1.5%) are shown at left; membranes were probed with anti-FLAG or anti-Rab12 antibodies. ( F ) Quantitation of two independent experiments carried out in duplicate as in ( E ). ****p<0.0001 for LRRK2 E240R and S244R relative to LRRK2 WT by one-way ANOVA. ( G ) Immunoblot analysis of 293T cells transfected with LRRK2 R1441C or K17/18A R1441G and GFP, GFP-Rab8, or GFP-Rab12 for 36 hr; +/-MLi2 (200 nM for 2 hr). ( H ) Quantitation of the fraction of phosphorylated Rab10 from immunoblots as in ( G ) normalized to respective total Rab10 levels, normalized to LRRK2 R1441C+GFP-Rab12. Error bars indicate SEM from two independent experiments; **p=0.003 for LRRK2 R1441C GFP and GFP-Rab12, **p=0.0044 for LRRK2 K17/18A R1441G GFP and GFP-Rab12, ns = 0.6 by Student’s t -test. Figure 8—source data 1. Raw/annotated gels for .

    Article Snippet: Recombinant DNA reagent , pCMV5 Flag-LRRK2 K17/18 A R1441G , Addgene RRID: Addgene_186012 , 186012 , .

    Techniques: Microscale Thermophoresis, Binding Assay, Labeling, Purification, Concentration Assay, Western Blot, Immunoprecipitation, Quantitation Assay, Transfection

    Journal: eLife

    Article Title: Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson’s disease-linked LRRK2 kinase

    doi: 10.7554/eLife.87098

    Figure Lengend Snippet:

    Article Snippet: Recombinant DNA reagent , pCMV5 Flag-LRRK2 K17/18 A R1441G , Addgene RRID: Addgene_186012 , 186012 , .

    Techniques: Bioprocessing, Generated, Labeling, Recombinant, Software

    LRRK2 G2019S mutation deregulates the TH–DA pathway, leading to DA neuron vulnerability. A – G LRRK2 enhances TH expression in PC12 cells in an LRRK2 kinase activity-dependent manner. A , C and F Representative Western blot data of up-regulated TH levels in PC12 cells under transient overexpression of WT, mutant G2019S or 3KD LRRK2. A FL LRRK2, C LRRK2 RCK domains and F LRRK2 kinase domain. B , D and G , Densitometric analysis of TH protein bands of Western blot gels in A , C and F , respectively. *, at least P < 0.01, compared with arbitrary value of TH protein bands of GFP-transfected control cells. E Quantitative real-time RT-PCR analysis of TH expression in PC12 cells under overexpression of WT, mutant G2019S or 3KD LRRK2 RCK domains. * P < 0.01, compared with relative TH expression level of GFP-transfected control cells. H Expression of WT and mutant G2019S LRRK2 RCK domains impair PC12 cell viability, which can be partially rescued by 500 µM GSH treatment. *, at least P < 0.01, compared with cell viability of the respective WT or G2019S RCK domains transfected PC12 cells in the absence of GSH treatment. (I–P) Stable transfection of LRRK2 up-regulates TH and DA levels, sensitizing human dopaminergic SH-SY5Y cells to stress challenges. I Representative Western blot TH protein bands in SH-SY5Y cells stably transfected with empty vector, WT or mutant G2019S FL LRRK2. J Densitometric analysis of Western blot TH protein bands in I . * P < 0.001, compared with arbitrary value of TH bands of empty vector transfected control SH-SY5Y cells. K and L Mutant G2019S LRRK2-induced DA content increase in stably transfected SH-SY5Y cells can be abrogated by treatment with 2 mM α-MT, a specific TH inhibitor. K Quantitative analysis of DA content by HPLC, *, at least P < 0.05, compared with DA content of the respective cells in the absence of α-MT. L Representative HPLC chromatography of DA peaks. M Quantitative real-time RT-PCR analysis of TH and LRRK2 expression level in stably transfected SH-SY5Y cells. *, at least P < 0.01, compared with TH and LRRK2 expression levels of empty vector transfected SH-SY5Y cells. N Stable transfection of mutant G2019S LRRK2 sensitizes SH-SY5Y cells to H 2 O 2 challenge. *, at least P < 0.05, compared with cell viability of empty vector transfected SH-SY5Y cells treated with the respective dosage of H 2 O 2 . ( O and P ) 2 mM α-MT treatment alleviates LRRK2-induced SH-SY5Y cell viability impairment under 100 µM Fe 2+ ( O ) or 100 µM Fe 3+ ( P ) challenges. *, at least P < 0.05, compared with cell death rate of the respective stable cells without iron species challenges. #, at least P < 0.05, compared with cell death rate of respective SH-SY5Y cells under the respective iron species challenges

    Journal: Cellular and Molecular Life Sciences

    Article Title: The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis

    doi: 10.1007/s00018-022-04574-x

    Figure Lengend Snippet: LRRK2 G2019S mutation deregulates the TH–DA pathway, leading to DA neuron vulnerability. A – G LRRK2 enhances TH expression in PC12 cells in an LRRK2 kinase activity-dependent manner. A , C and F Representative Western blot data of up-regulated TH levels in PC12 cells under transient overexpression of WT, mutant G2019S or 3KD LRRK2. A FL LRRK2, C LRRK2 RCK domains and F LRRK2 kinase domain. B , D and G , Densitometric analysis of TH protein bands of Western blot gels in A , C and F , respectively. *, at least P < 0.01, compared with arbitrary value of TH protein bands of GFP-transfected control cells. E Quantitative real-time RT-PCR analysis of TH expression in PC12 cells under overexpression of WT, mutant G2019S or 3KD LRRK2 RCK domains. * P < 0.01, compared with relative TH expression level of GFP-transfected control cells. H Expression of WT and mutant G2019S LRRK2 RCK domains impair PC12 cell viability, which can be partially rescued by 500 µM GSH treatment. *, at least P < 0.01, compared with cell viability of the respective WT or G2019S RCK domains transfected PC12 cells in the absence of GSH treatment. (I–P) Stable transfection of LRRK2 up-regulates TH and DA levels, sensitizing human dopaminergic SH-SY5Y cells to stress challenges. I Representative Western blot TH protein bands in SH-SY5Y cells stably transfected with empty vector, WT or mutant G2019S FL LRRK2. J Densitometric analysis of Western blot TH protein bands in I . * P < 0.001, compared with arbitrary value of TH bands of empty vector transfected control SH-SY5Y cells. K and L Mutant G2019S LRRK2-induced DA content increase in stably transfected SH-SY5Y cells can be abrogated by treatment with 2 mM α-MT, a specific TH inhibitor. K Quantitative analysis of DA content by HPLC, *, at least P < 0.05, compared with DA content of the respective cells in the absence of α-MT. L Representative HPLC chromatography of DA peaks. M Quantitative real-time RT-PCR analysis of TH and LRRK2 expression level in stably transfected SH-SY5Y cells. *, at least P < 0.01, compared with TH and LRRK2 expression levels of empty vector transfected SH-SY5Y cells. N Stable transfection of mutant G2019S LRRK2 sensitizes SH-SY5Y cells to H 2 O 2 challenge. *, at least P < 0.05, compared with cell viability of empty vector transfected SH-SY5Y cells treated with the respective dosage of H 2 O 2 . ( O and P ) 2 mM α-MT treatment alleviates LRRK2-induced SH-SY5Y cell viability impairment under 100 µM Fe 2+ ( O ) or 100 µM Fe 3+ ( P ) challenges. *, at least P < 0.05, compared with cell death rate of the respective stable cells without iron species challenges. #, at least P < 0.05, compared with cell death rate of respective SH-SY5Y cells under the respective iron species challenges

    Article Snippet: LRRK2 R1441G TG mice generated from BAC containing the entire human mutant R1441G LRRK2 were also provided by the Jackson Laboratory (#009604) [ ].

    Techniques: Mutagenesis, Expressing, Activity Assay, Western Blot, Over Expression, Transfection, Control, Quantitative RT-PCR, Stable Transfection, Plasmid Preparation, Chromatography

    LRRK2 G2019S mutation deregulates the TH–DA pathway, contributing to DA neurodegeneration in Drosophila PD model. Yellow white control, LRRK2 TG Drosophila and LRRK2 RNAi Drosophila lines are crossed with ddc-GAL4 line to modulate LRRK2 expression in Drosophila head DA neurons and cultured for different time periods. A Locomotor deficits of climbing ability of Drosophila with or without TG expression of human WT and G2019S LRRK2 in Drosophila head DA neurons after 1 day and 60 days culture. *, at least P < 0.05, compared with the percentage of Drosophila on top of the control group. B Representative confocal image of TH neurons in Drosophila heads of control and LRRK2 TG Drosophila cultured for 1 day or 60 days. C HPLC analysis of DA content in Drosophila heads of control and LRRK2 TG Drosophila at different culture time points. *, at least P < 0.05, compared with DA content in Drosophila heads of control group at the respective time points. D and E Number of TH-positive dopaminergic neurons in Drosophila heads cultured for 1 day ( D ) and 60 days ( E ), *, at least P < 0.05, compared with the number of TH positive neurons in control Drosophila heads cultured for 60 days. F HPLC analysis of DA content in Drosophila heads of control and LRRK2 RNAi Drosophila lines. * P < 0.05, compared with DA content in Drosophila heads of control group at the respective culture time points. G Representative Western blot TH levels in Drosophila heads of 3 days cultured control, TG LRRK2 and LRRK2 RNAi Drosophila lines. H Densitometric analysis of TH bands in Western blot gels in G. *, at least P < 0.05, compared with the arbitrary value of TH bands in control Drosophila heads

    Journal: Cellular and Molecular Life Sciences

    Article Title: The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis

    doi: 10.1007/s00018-022-04574-x

    Figure Lengend Snippet: LRRK2 G2019S mutation deregulates the TH–DA pathway, contributing to DA neurodegeneration in Drosophila PD model. Yellow white control, LRRK2 TG Drosophila and LRRK2 RNAi Drosophila lines are crossed with ddc-GAL4 line to modulate LRRK2 expression in Drosophila head DA neurons and cultured for different time periods. A Locomotor deficits of climbing ability of Drosophila with or without TG expression of human WT and G2019S LRRK2 in Drosophila head DA neurons after 1 day and 60 days culture. *, at least P < 0.05, compared with the percentage of Drosophila on top of the control group. B Representative confocal image of TH neurons in Drosophila heads of control and LRRK2 TG Drosophila cultured for 1 day or 60 days. C HPLC analysis of DA content in Drosophila heads of control and LRRK2 TG Drosophila at different culture time points. *, at least P < 0.05, compared with DA content in Drosophila heads of control group at the respective time points. D and E Number of TH-positive dopaminergic neurons in Drosophila heads cultured for 1 day ( D ) and 60 days ( E ), *, at least P < 0.05, compared with the number of TH positive neurons in control Drosophila heads cultured for 60 days. F HPLC analysis of DA content in Drosophila heads of control and LRRK2 RNAi Drosophila lines. * P < 0.05, compared with DA content in Drosophila heads of control group at the respective culture time points. G Representative Western blot TH levels in Drosophila heads of 3 days cultured control, TG LRRK2 and LRRK2 RNAi Drosophila lines. H Densitometric analysis of TH bands in Western blot gels in G. *, at least P < 0.05, compared with the arbitrary value of TH bands in control Drosophila heads

    Article Snippet: LRRK2 R1441G TG mice generated from BAC containing the entire human mutant R1441G LRRK2 were also provided by the Jackson Laboratory (#009604) [ ].

    Techniques: Mutagenesis, Control, Expressing, Cell Culture, Western Blot

    LRRK2 G2019S mutation-induced Drosophila DA neurodegeneration can be abrogated by α-MT, a TH inhibitor. Yellow white control and WT or mutant G2019S LRRK2 TG Drosophila are crossed with ddc-GAL4 line and cultured in the presence or absence of 15 µM α-MT for 30 days. A α-MT treatment can improve locomotor deficits of climbing ability of TG mutant G2019S LRRK2 Drosophila . * P < 0.01, compared with the percentage of Drosophila on top of control group in the absence of α-MT. B α-MT treatment can prevent mutant G2019S LRRK2-induced DA content decrease in Drosophila heads. *, at least P < 0.05, compared with DA content in Drosophila heads of control group in the absence ofα-MT. C α-MT treatment can protect against DA neurodegeneration in mutant G2019S LRRK2 Drosophila heads. *, at least P < 0.05, compared with the number of TH-positive neurons in control Drosophila heads. D Representative confocal image of TH neurons in Drosophila heads of control and LRRK2 transgenic Drosophila cultured for 60 days. E Representative Western blot gels of DA-conjugated proteins and DNP-positive proteins in control and LRRK2 TG Drosophila heads after culture for 3 days or 30 days

    Journal: Cellular and Molecular Life Sciences

    Article Title: The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis

    doi: 10.1007/s00018-022-04574-x

    Figure Lengend Snippet: LRRK2 G2019S mutation-induced Drosophila DA neurodegeneration can be abrogated by α-MT, a TH inhibitor. Yellow white control and WT or mutant G2019S LRRK2 TG Drosophila are crossed with ddc-GAL4 line and cultured in the presence or absence of 15 µM α-MT for 30 days. A α-MT treatment can improve locomotor deficits of climbing ability of TG mutant G2019S LRRK2 Drosophila . * P < 0.01, compared with the percentage of Drosophila on top of control group in the absence of α-MT. B α-MT treatment can prevent mutant G2019S LRRK2-induced DA content decrease in Drosophila heads. *, at least P < 0.05, compared with DA content in Drosophila heads of control group in the absence ofα-MT. C α-MT treatment can protect against DA neurodegeneration in mutant G2019S LRRK2 Drosophila heads. *, at least P < 0.05, compared with the number of TH-positive neurons in control Drosophila heads. D Representative confocal image of TH neurons in Drosophila heads of control and LRRK2 transgenic Drosophila cultured for 60 days. E Representative Western blot gels of DA-conjugated proteins and DNP-positive proteins in control and LRRK2 TG Drosophila heads after culture for 3 days or 30 days

    Article Snippet: LRRK2 R1441G TG mice generated from BAC containing the entire human mutant R1441G LRRK2 were also provided by the Jackson Laboratory (#009604) [ ].

    Techniques: Mutagenesis, Control, Cell Culture, Transgenic Assay, Western Blot

    PD-linked LRRK2 mutations-induced deregulation of the TH–DA pathway in TG mice models. A – F G2019S LRRK2 mutation induces age-relevant alterations of TH and DA levels in transgenic mice midbrains. A – D Western blot data of TH protein levels in TG mice midbrains. A 3 months (3 mth), B 6 months (6mth), C 12 months (12 mth), D 20 months (20 mth). E Densitometric analysis of TH protein bands in Western blot gels in A–E. *, at least P < 0.05, compared with arbitrary value of TH bands of non-TG mice. F HPLC analysis of DA content in 7 days postnatal (P7) whole brain and 12 mth midbrain of mice. * P < 0.05, compared with DA content in non-TG mice brains. G – I Mutant R1441G LRRK2 induces age-relevant alterations of TH and DA levels in TG mice brains. G Representative Western blot TH bands in mice cortex. H Densitometric analysis of TH bands in Western blot gels in H. *, at least P < 0.05, compared with arbitrary value of TH bands in non-TG mice brains. I HPLC analysis of DA content in the striatum of 3 month- and 14 month-old mice. *, at least P < 0.05, compared with DA content in striatum of non-TG mice. J – L Age-dependent accumulation of DA-conjugated proteins in non-TG and TG mice midbrains. J 12 months, K 18 months, L , 21 months

    Journal: Cellular and Molecular Life Sciences

    Article Title: The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis

    doi: 10.1007/s00018-022-04574-x

    Figure Lengend Snippet: PD-linked LRRK2 mutations-induced deregulation of the TH–DA pathway in TG mice models. A – F G2019S LRRK2 mutation induces age-relevant alterations of TH and DA levels in transgenic mice midbrains. A – D Western blot data of TH protein levels in TG mice midbrains. A 3 months (3 mth), B 6 months (6mth), C 12 months (12 mth), D 20 months (20 mth). E Densitometric analysis of TH protein bands in Western blot gels in A–E. *, at least P < 0.05, compared with arbitrary value of TH bands of non-TG mice. F HPLC analysis of DA content in 7 days postnatal (P7) whole brain and 12 mth midbrain of mice. * P < 0.05, compared with DA content in non-TG mice brains. G – I Mutant R1441G LRRK2 induces age-relevant alterations of TH and DA levels in TG mice brains. G Representative Western blot TH bands in mice cortex. H Densitometric analysis of TH bands in Western blot gels in H. *, at least P < 0.05, compared with arbitrary value of TH bands in non-TG mice brains. I HPLC analysis of DA content in the striatum of 3 month- and 14 month-old mice. *, at least P < 0.05, compared with DA content in striatum of non-TG mice. J – L Age-dependent accumulation of DA-conjugated proteins in non-TG and TG mice midbrains. J 12 months, K 18 months, L , 21 months

    Article Snippet: LRRK2 R1441G TG mice generated from BAC containing the entire human mutant R1441G LRRK2 were also provided by the Jackson Laboratory (#009604) [ ].

    Techniques: Mutagenesis, Transgenic Assay, Western Blot

    LRRK2 G2019S mutation-induced deregulation of the TH–DA pathway and DA neuron demise in human patient iPSc-derived DA neuron and hMLOs models. A – C G2019S LRRK2 increases TH and DA levels in iPSc-derived DA neurons after 42 days induction and culture. A Representative Western blot data of TH levels in DA neurons. B Densitometric analysis of TH protein bands in Western blot gels in A. * P < 0.001, compared with arbitrary value of TH protein band of WT LRRK2 DA neurons, C HPLC analysis of DA content in DA neurons. * P < 0.05, compared with DA content in WT LRRK2 DA neurons. D – F Mutant G2019S LRRK2 increases TH and DA levels in iPSc-derived hMLOs after 60 days induction and culture. D Representative Western blot data of TH levels in hMLOs. E Densitometric analysis of TH protein bands in Western blot gels in D . * P < 0.001, compared with arbitrary value of TH protein bands of WT LRRK2 hMLOs. F HPLC analysis of DA content in hMLOs. * P < 0.05, compared with DA content of WT LRRK2 hMLOs. G and H Mutant G2019S LRRK2 leads to decreased TH level in longer time cultured hMLOs. G Western blot TH protein bands in hMLOs after induction and culture for 90 and 127 days. H Densitometric analysis of TH bands in Western blot gels in G . * P < 0.001, compared with arbitrary value of TH bands of the respective WT or mutant G2019S LRRK2 hMLOs cultured for 90 days. #, at least P < 0.05, compared with arbitrary value of TH bands of WT LRRK2 hMLOs cultured for 90 or 127 days, respectively. I – K Mutant G2019S LRRK2 induces DA neurodegeneration in hMLOs. I and J Ratio of TH I or activated caspase 3- ( J ) positive cells against DAPI-stained cells. *, at least P < 0.005, compared with ratio of TH or activated caspase 3-positive cells against DAPI-stained cells of WT LRRK2 hMLOs. K Representative confocal image of TH, activated caspase 3 and DAPI-stained hMLOs (magnification: 400×)

    Journal: Cellular and Molecular Life Sciences

    Article Title: The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis

    doi: 10.1007/s00018-022-04574-x

    Figure Lengend Snippet: LRRK2 G2019S mutation-induced deregulation of the TH–DA pathway and DA neuron demise in human patient iPSc-derived DA neuron and hMLOs models. A – C G2019S LRRK2 increases TH and DA levels in iPSc-derived DA neurons after 42 days induction and culture. A Representative Western blot data of TH levels in DA neurons. B Densitometric analysis of TH protein bands in Western blot gels in A. * P < 0.001, compared with arbitrary value of TH protein band of WT LRRK2 DA neurons, C HPLC analysis of DA content in DA neurons. * P < 0.05, compared with DA content in WT LRRK2 DA neurons. D – F Mutant G2019S LRRK2 increases TH and DA levels in iPSc-derived hMLOs after 60 days induction and culture. D Representative Western blot data of TH levels in hMLOs. E Densitometric analysis of TH protein bands in Western blot gels in D . * P < 0.001, compared with arbitrary value of TH protein bands of WT LRRK2 hMLOs. F HPLC analysis of DA content in hMLOs. * P < 0.05, compared with DA content of WT LRRK2 hMLOs. G and H Mutant G2019S LRRK2 leads to decreased TH level in longer time cultured hMLOs. G Western blot TH protein bands in hMLOs after induction and culture for 90 and 127 days. H Densitometric analysis of TH bands in Western blot gels in G . * P < 0.001, compared with arbitrary value of TH bands of the respective WT or mutant G2019S LRRK2 hMLOs cultured for 90 days. #, at least P < 0.05, compared with arbitrary value of TH bands of WT LRRK2 hMLOs cultured for 90 or 127 days, respectively. I – K Mutant G2019S LRRK2 induces DA neurodegeneration in hMLOs. I and J Ratio of TH I or activated caspase 3- ( J ) positive cells against DAPI-stained cells. *, at least P < 0.005, compared with ratio of TH or activated caspase 3-positive cells against DAPI-stained cells of WT LRRK2 hMLOs. K Representative confocal image of TH, activated caspase 3 and DAPI-stained hMLOs (magnification: 400×)

    Article Snippet: LRRK2 R1441G TG mice generated from BAC containing the entire human mutant R1441G LRRK2 were also provided by the Jackson Laboratory (#009604) [ ].

    Techniques: Mutagenesis, Derivative Assay, Western Blot, Cell Culture, Staining

    LRRK2 and PINK1 reversely modulate the TH–DA pathway and PD-like symptoms in Drosophila PD models. Control yellow white or TG Drosophila are crossed with ddc-GAL4 to induce expressions of human PINK1 and/or LRRK2 in DA neurons in Drosophila heads. Drosophila heads are harvested after 3 days culture, homogenized and subjected to Western blot analysis of TH protein and HPLC analysis of DA content. A and B WT PINK1 suppresses TH expression in Drosophila heads. A Western blot data of TH bands in Drosophila heads of control and TG WT PINK1 Drosophila . B Densitometric analysis of TH bands in Western blot gels in A. *, at least P < 0.05, compared with the arbitrary value of TH bands in control Drosophila heads. C and D Mutant G309D PINK1 up-regulates TH expression in Drosophila heads. C Western blot data of TH levels in Drosophila heads of control and TG mutant G309D PINK1 Drosophila . D Densitometric analysis of TH bands in Western blot gels in C . * P < 0.05, compared with the arbitrary value of TH bands in control Drosophila heads. E and F HPLC analysis of DA content in Drosophila heads of control and TG WT PINK1 ( E ) and mutant G309D ( F ) Drosophila . *, at least P < 0.05, compared with DA content in Drosophila heads of control Drosophila . G – J Regulations of TH expression and DA content in Drosophila heads by WT or mutant PINK1 and/or LRRK2. G and H WT, but not G309D PINK1, can alleviate mutant G2019S LRRK2-induced up-regulation of TH expression level in Drosophila heads. G Western blot data of TH levels in Drosophila heads of control, mutant G2019S LRRK2, mutant G2019S LRRK2 plus WT or mutant G309D PINK1 double TG Drosophila . B Densitometric analysis of TH bands in Western blot gels in A. *, at least P < 0.05, compared with the arbitrary value of TH protein bands in control Drosophila heads. I WT PINK1 can alleviate mutant G2019S LRRK2-induced PD-like symptoms. *, at least P < 0.05, compared with the percentage of Drosophila on top of control Drosophila cultured for 40 or 60 days, respectively. J HPLC analysis of DA content in Drosophila heads of control, and transgenic WT and mutant PINK1 and/or LRRK2 Drosophila lines. *, at least P < 0.05, compared with DA content in Drosophila heads of control Drosophila cultured for the respective days

    Journal: Cellular and Molecular Life Sciences

    Article Title: The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis

    doi: 10.1007/s00018-022-04574-x

    Figure Lengend Snippet: LRRK2 and PINK1 reversely modulate the TH–DA pathway and PD-like symptoms in Drosophila PD models. Control yellow white or TG Drosophila are crossed with ddc-GAL4 to induce expressions of human PINK1 and/or LRRK2 in DA neurons in Drosophila heads. Drosophila heads are harvested after 3 days culture, homogenized and subjected to Western blot analysis of TH protein and HPLC analysis of DA content. A and B WT PINK1 suppresses TH expression in Drosophila heads. A Western blot data of TH bands in Drosophila heads of control and TG WT PINK1 Drosophila . B Densitometric analysis of TH bands in Western blot gels in A. *, at least P < 0.05, compared with the arbitrary value of TH bands in control Drosophila heads. C and D Mutant G309D PINK1 up-regulates TH expression in Drosophila heads. C Western blot data of TH levels in Drosophila heads of control and TG mutant G309D PINK1 Drosophila . D Densitometric analysis of TH bands in Western blot gels in C . * P < 0.05, compared with the arbitrary value of TH bands in control Drosophila heads. E and F HPLC analysis of DA content in Drosophila heads of control and TG WT PINK1 ( E ) and mutant G309D ( F ) Drosophila . *, at least P < 0.05, compared with DA content in Drosophila heads of control Drosophila . G – J Regulations of TH expression and DA content in Drosophila heads by WT or mutant PINK1 and/or LRRK2. G and H WT, but not G309D PINK1, can alleviate mutant G2019S LRRK2-induced up-regulation of TH expression level in Drosophila heads. G Western blot data of TH levels in Drosophila heads of control, mutant G2019S LRRK2, mutant G2019S LRRK2 plus WT or mutant G309D PINK1 double TG Drosophila . B Densitometric analysis of TH bands in Western blot gels in A. *, at least P < 0.05, compared with the arbitrary value of TH protein bands in control Drosophila heads. I WT PINK1 can alleviate mutant G2019S LRRK2-induced PD-like symptoms. *, at least P < 0.05, compared with the percentage of Drosophila on top of control Drosophila cultured for 40 or 60 days, respectively. J HPLC analysis of DA content in Drosophila heads of control, and transgenic WT and mutant PINK1 and/or LRRK2 Drosophila lines. *, at least P < 0.05, compared with DA content in Drosophila heads of control Drosophila cultured for the respective days

    Article Snippet: LRRK2 R1441G TG mice generated from BAC containing the entire human mutant R1441G LRRK2 were also provided by the Jackson Laboratory (#009604) [ ].

    Techniques: Control, Western Blot, Expressing, Mutagenesis, Cell Culture, Transgenic Assay

    LRRK2 down-regulates PINK1 protein level via facilitation of PINK1 protein degradation in an LRRK2 kinase activity-dependent manner. A – C LRRK2 KO up-regulates PINK1 protein level in human HAP1 cells. A Representative Western blot data of PINK1 levels in LRRK2 KO HAP1 cells. B Densitometric analysis of red arrowhead-pointed PINK1 bands in Western blot gels in A . *, P < 0.01, compared with the arbitrary value of PINK1 bands in control HAP1 cells. C LRRK2 KO has no influence on PINK1 transcription level in HAP1 cells, demonstrated by quantitative real-time RT-PCR analysis. * P < 0.001, compared with the expression level of PINK1 in control HAP1 cells. D – F Stable transfection of WT and mutant G2019S LRRK2 down-regulates PINK1 protein level in SH-SY5Y cells. D Western blot data of PINK1 bands in empty vector, WT or mutant G2019S LRRK2 stably transfected cells. E Densitometric analysis of red arrowhead-pointed PINK1 bands in Western blot gels in D . *, P < 0.001, compared with the arbitrary value of PINK1 bands in empty vector transfected cells. F Quantitative real-time RT-PCR analysis showed that stable transfection of WT and mutant G2019S LRRK2 had no impact on PINK1 transcription level in cells. * P < 0.001, compared with LRRK2 transcription level of empty vector transfected cells. G – J Human WT and mutant G2019S LRRK2 down-regulate PINK1 protein level in LRRK2/PINK1 double TG Drosophila heads. Single or double TG LRRK2 and/or PINK1 lines are crossed with ddc-GAL4 line to induce expressions of PINK1 and or LRRK2 in DA neurons in Drosophila heads. Drosophila heads are harvested after 3 days culture, homogenized and subjected to Western blot analysis of PINK1 protein level. G – I Representative Western blot data of PINK1 level in Drosophila heads of control, WT or G309D PINK1, WT or mutant G2019S LRRK2 single or double TG Drosophila . G WT PINK1 and/or WT or mutant G2019S LRRK2; H mutant G309D PINK1 and/or mutant G2019S LRRK2 Drosophila . I Mutant G309D PINK1 and or WT LRRK2 Drosophila . J Densitometric analysis of red arrowhead-pointed PINK1 protein bands in Western blot gels in G , H and I . *, at least P < 0.05, compared with the arbitrary value of PINK1 bands in single WT or mutant G309D PINK1 TG Drosophila . K and L Mutant G2019S LRRK2 down-regulates PINK1 protein level in iPSc derived hMLOs. K Western blot data of PINK1 levels in hMLOs with mutant G2019S LRRK2 after 60 days induction and culture. L Densitometric analysis of red arrowhead-pointed PINK1 bands in Western blot gels in J. *, P < 0.05, compared with the arbitrary value of PINK1 bands of hMLOs with WT LRRK2. M and N , mutant G2019S LRRK2 down-regulates PINK1 protein level in iPSc derived human DA neurons. M Western blot data of modulated PINK1 levels in human DA neurons with mutant G2019S LRRK2 after 42 days induction and culture. N Densitometric analysis of red arrow head pointed PINK1 bands in Western blot gels in L. * P < 0.0001, compared with the arbitrary value of PINK1 protein bands of human DA neurons with WT LRRK2. O and P Mutant G2019S LRRK2 down-regulates PINK1 protein level in mutant G2019S LRRK2 TG mice cortex. O Representative Western blot data of modulated PINK1 protein levels in 6 month aged TG mice cortex by mutant G2019S LRRK2. P Densitometric analysis of red arrow head pointed PINK1 bands in Western blot gels in O. * P < 0.001, compared with the arbitrary value of PINK1 protein bands of control non-transgenic mice. Q – R Mutant G2019S LRRK2 promotes proteasome degradation of PINK1 protein in SH-SY5Y cells. Q Representative Western blot data of PINK1 levels in empty vector or mutant G2019S LRRK stably transfected cells in the presence or absence of 3 µM proteasome inhibitor MG132 for 6 h. R Densitometric analysis of red arrowhead-pointed PINK1 bands in Western blot gels in Q . *, at least P < 0.001, compared with the arbitrary value of PINK1 bands of respective cells without MG132 treatment. #, at least P < 0.001, compared with the arbitrary value of PINK1 bands of empty vector transfected cells with or without MG132 treatment, respectively

    Journal: Cellular and Molecular Life Sciences

    Article Title: The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis

    doi: 10.1007/s00018-022-04574-x

    Figure Lengend Snippet: LRRK2 down-regulates PINK1 protein level via facilitation of PINK1 protein degradation in an LRRK2 kinase activity-dependent manner. A – C LRRK2 KO up-regulates PINK1 protein level in human HAP1 cells. A Representative Western blot data of PINK1 levels in LRRK2 KO HAP1 cells. B Densitometric analysis of red arrowhead-pointed PINK1 bands in Western blot gels in A . *, P < 0.01, compared with the arbitrary value of PINK1 bands in control HAP1 cells. C LRRK2 KO has no influence on PINK1 transcription level in HAP1 cells, demonstrated by quantitative real-time RT-PCR analysis. * P < 0.001, compared with the expression level of PINK1 in control HAP1 cells. D – F Stable transfection of WT and mutant G2019S LRRK2 down-regulates PINK1 protein level in SH-SY5Y cells. D Western blot data of PINK1 bands in empty vector, WT or mutant G2019S LRRK2 stably transfected cells. E Densitometric analysis of red arrowhead-pointed PINK1 bands in Western blot gels in D . *, P < 0.001, compared with the arbitrary value of PINK1 bands in empty vector transfected cells. F Quantitative real-time RT-PCR analysis showed that stable transfection of WT and mutant G2019S LRRK2 had no impact on PINK1 transcription level in cells. * P < 0.001, compared with LRRK2 transcription level of empty vector transfected cells. G – J Human WT and mutant G2019S LRRK2 down-regulate PINK1 protein level in LRRK2/PINK1 double TG Drosophila heads. Single or double TG LRRK2 and/or PINK1 lines are crossed with ddc-GAL4 line to induce expressions of PINK1 and or LRRK2 in DA neurons in Drosophila heads. Drosophila heads are harvested after 3 days culture, homogenized and subjected to Western blot analysis of PINK1 protein level. G – I Representative Western blot data of PINK1 level in Drosophila heads of control, WT or G309D PINK1, WT or mutant G2019S LRRK2 single or double TG Drosophila . G WT PINK1 and/or WT or mutant G2019S LRRK2; H mutant G309D PINK1 and/or mutant G2019S LRRK2 Drosophila . I Mutant G309D PINK1 and or WT LRRK2 Drosophila . J Densitometric analysis of red arrowhead-pointed PINK1 protein bands in Western blot gels in G , H and I . *, at least P < 0.05, compared with the arbitrary value of PINK1 bands in single WT or mutant G309D PINK1 TG Drosophila . K and L Mutant G2019S LRRK2 down-regulates PINK1 protein level in iPSc derived hMLOs. K Western blot data of PINK1 levels in hMLOs with mutant G2019S LRRK2 after 60 days induction and culture. L Densitometric analysis of red arrowhead-pointed PINK1 bands in Western blot gels in J. *, P < 0.05, compared with the arbitrary value of PINK1 bands of hMLOs with WT LRRK2. M and N , mutant G2019S LRRK2 down-regulates PINK1 protein level in iPSc derived human DA neurons. M Western blot data of modulated PINK1 levels in human DA neurons with mutant G2019S LRRK2 after 42 days induction and culture. N Densitometric analysis of red arrow head pointed PINK1 bands in Western blot gels in L. * P < 0.0001, compared with the arbitrary value of PINK1 protein bands of human DA neurons with WT LRRK2. O and P Mutant G2019S LRRK2 down-regulates PINK1 protein level in mutant G2019S LRRK2 TG mice cortex. O Representative Western blot data of modulated PINK1 protein levels in 6 month aged TG mice cortex by mutant G2019S LRRK2. P Densitometric analysis of red arrow head pointed PINK1 bands in Western blot gels in O. * P < 0.001, compared with the arbitrary value of PINK1 protein bands of control non-transgenic mice. Q – R Mutant G2019S LRRK2 promotes proteasome degradation of PINK1 protein in SH-SY5Y cells. Q Representative Western blot data of PINK1 levels in empty vector or mutant G2019S LRRK stably transfected cells in the presence or absence of 3 µM proteasome inhibitor MG132 for 6 h. R Densitometric analysis of red arrowhead-pointed PINK1 bands in Western blot gels in Q . *, at least P < 0.001, compared with the arbitrary value of PINK1 bands of respective cells without MG132 treatment. #, at least P < 0.001, compared with the arbitrary value of PINK1 bands of empty vector transfected cells with or without MG132 treatment, respectively

    Article Snippet: LRRK2 R1441G TG mice generated from BAC containing the entire human mutant R1441G LRRK2 were also provided by the Jackson Laboratory (#009604) [ ].

    Techniques: Activity Assay, Western Blot, Control, Quantitative RT-PCR, Expressing, Stable Transfection, Mutagenesis, Plasmid Preparation, Transfection, Derivative Assay, Transgenic Assay

    PINK1 down-regulates LRRK2 protein level via facilitation of LRRK2 protein degradation in a PINK 1 kinase activity-dependent manner. A – C PINK1 KO up-regulate LRRK2 protein level in human HAP1 cells. A Representative Western blot data of LRRK2 levels in PINK1 KO HAP1 cells. B Densitometric analysis of LRRK2 bands in Western blot gels in A . * P < 0.01, compared with the arbitrary value of LRRK2 bands in control HAP1 cells. C PINK1 KO has no influence on LRRK2 transcript level in HAP1 cells. * P < 0.001, compared with the expression level of PINK1 in control HAP1 cells. D – F Stable transfection of WT PINK1 down-regulate LRRK2 protein level, whereas stable transfection of mutant A339T or E231G PINK1 up-regulate LRRK2 protein level in SH-SY5Y cells. D Representative Western blot data of LRRK2 level in empty vector, WT or mutant A339T or E231G PINK1 stably transfected cells. E Densitometric analysis of LRRK2 bands in Western blot gels in D. *, at least P < 0.05, compared with the arbitrary value of LRRK2 protein bands in empty vector transfected cells. F Quantitative real-time RT-PCR analysis of PINK1 and LRRK2 expression in stably transfected cells. *, at least P < 0.001, compared with PINK1 transcript level of empty vector transfected cells. G – J WT, but not mutant G309D PINK1 down-regulate LRRK2 protein level in double TG Drosophila heads. Single or double TG WT or mutant LRRK2 and/or PINK1 lines are crossed with ddc-GAL4 line to induce expressions of PINK1 and/or LRRK2 in DA neurons in Drosophila heads. Drosophila heads are harvested after 3 days culture, homogenized and subjected to Western blot analysis of PINK1 protein level. G – I Representative Western blot data of LRRK2 bands in Drosophila heads of control, single or double TG Drosophila . G Mutant G309D PINK1 and/or mutant G2019S LRRK2 Drosophila ; H mutant G309D PINK1 and/or WT LRRK2 Drosophila ; I WT PINK1 and/or WT or mutant G2019S LRRK2 Drosophila . J Densitometric analysis of LRRK2 bands in Western blot gels in G , H and I . *, at least P < 0.01, compared with the arbitrary value of LRRK2 bands in Drosophila heads of WT or mutant G2019S LRRK2 single TG Drosophila . ( K and L ) WT PINK1 promotes proteasome degradation of LRRK2 protein in SH-SY5Y cells. K Representative Western blot data of LRRK2 levels in empty vector or WT PINK1 stably transfected cells treated with or without 3 µM MG132 for 6 h. L Densitometric analysis of LRRK2 bands in Western blot gels in K . *, at least P < 0.05, compared with the arbitrary value of LRRK2 bands of respective cells without MG132 treatment. # P < 0.05, compared with the arbitrary value of LRRK2 bands of empty vector transfected cells without MG132 treatment

    Journal: Cellular and Molecular Life Sciences

    Article Title: The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis

    doi: 10.1007/s00018-022-04574-x

    Figure Lengend Snippet: PINK1 down-regulates LRRK2 protein level via facilitation of LRRK2 protein degradation in a PINK 1 kinase activity-dependent manner. A – C PINK1 KO up-regulate LRRK2 protein level in human HAP1 cells. A Representative Western blot data of LRRK2 levels in PINK1 KO HAP1 cells. B Densitometric analysis of LRRK2 bands in Western blot gels in A . * P < 0.01, compared with the arbitrary value of LRRK2 bands in control HAP1 cells. C PINK1 KO has no influence on LRRK2 transcript level in HAP1 cells. * P < 0.001, compared with the expression level of PINK1 in control HAP1 cells. D – F Stable transfection of WT PINK1 down-regulate LRRK2 protein level, whereas stable transfection of mutant A339T or E231G PINK1 up-regulate LRRK2 protein level in SH-SY5Y cells. D Representative Western blot data of LRRK2 level in empty vector, WT or mutant A339T or E231G PINK1 stably transfected cells. E Densitometric analysis of LRRK2 bands in Western blot gels in D. *, at least P < 0.05, compared with the arbitrary value of LRRK2 protein bands in empty vector transfected cells. F Quantitative real-time RT-PCR analysis of PINK1 and LRRK2 expression in stably transfected cells. *, at least P < 0.001, compared with PINK1 transcript level of empty vector transfected cells. G – J WT, but not mutant G309D PINK1 down-regulate LRRK2 protein level in double TG Drosophila heads. Single or double TG WT or mutant LRRK2 and/or PINK1 lines are crossed with ddc-GAL4 line to induce expressions of PINK1 and/or LRRK2 in DA neurons in Drosophila heads. Drosophila heads are harvested after 3 days culture, homogenized and subjected to Western blot analysis of PINK1 protein level. G – I Representative Western blot data of LRRK2 bands in Drosophila heads of control, single or double TG Drosophila . G Mutant G309D PINK1 and/or mutant G2019S LRRK2 Drosophila ; H mutant G309D PINK1 and/or WT LRRK2 Drosophila ; I WT PINK1 and/or WT or mutant G2019S LRRK2 Drosophila . J Densitometric analysis of LRRK2 bands in Western blot gels in G , H and I . *, at least P < 0.01, compared with the arbitrary value of LRRK2 bands in Drosophila heads of WT or mutant G2019S LRRK2 single TG Drosophila . ( K and L ) WT PINK1 promotes proteasome degradation of LRRK2 protein in SH-SY5Y cells. K Representative Western blot data of LRRK2 levels in empty vector or WT PINK1 stably transfected cells treated with or without 3 µM MG132 for 6 h. L Densitometric analysis of LRRK2 bands in Western blot gels in K . *, at least P < 0.05, compared with the arbitrary value of LRRK2 bands of respective cells without MG132 treatment. # P < 0.05, compared with the arbitrary value of LRRK2 bands of empty vector transfected cells without MG132 treatment

    Article Snippet: LRRK2 R1441G TG mice generated from BAC containing the entire human mutant R1441G LRRK2 were also provided by the Jackson Laboratory (#009604) [ ].

    Techniques: Activity Assay, Western Blot, Control, Expressing, Stable Transfection, Mutagenesis, Plasmid Preparation, Transfection, Quantitative RT-PCR

    Illustration of the role of LRRK2–PINK1 on TH expression and DA synthesis in DA neurons. Under physiological conditions, LRRK2 and PINK1 form a functional balance to maintain normal TH expression and DA synthesis in DA neurons. LRRK2 promotes TH expression and DA generation, while PINK1 suppresses TH expression and DA generation. LRRK2 and PINK1 can regulate degradation of each other, and thus a balance can be reached. When LRRK2 is mutated, its kinase activity is increased, leading to up-regulated TH expression and increased DA generation. Increased LRRK2 kinase activity can facilitate PINK1 degradation, down-regulate PINK1 level and suppress PINK1 function. This will lead to imbalance between LRRK2 and PINK1, contributing to increased TH expression, enhanced DA generation, aggravated DA oxidation and elevated DA-relevant stress in DA neurons, promoting neurodegeneration. When PINK1 is mutated, kinase activity will be impaired causing LRRK2–PINK1 imbalance and disrupting the TH–DA pathway, promoting DA neuron vulnerability and neurodegeneration

    Journal: Cellular and Molecular Life Sciences

    Article Title: The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis

    doi: 10.1007/s00018-022-04574-x

    Figure Lengend Snippet: Illustration of the role of LRRK2–PINK1 on TH expression and DA synthesis in DA neurons. Under physiological conditions, LRRK2 and PINK1 form a functional balance to maintain normal TH expression and DA synthesis in DA neurons. LRRK2 promotes TH expression and DA generation, while PINK1 suppresses TH expression and DA generation. LRRK2 and PINK1 can regulate degradation of each other, and thus a balance can be reached. When LRRK2 is mutated, its kinase activity is increased, leading to up-regulated TH expression and increased DA generation. Increased LRRK2 kinase activity can facilitate PINK1 degradation, down-regulate PINK1 level and suppress PINK1 function. This will lead to imbalance between LRRK2 and PINK1, contributing to increased TH expression, enhanced DA generation, aggravated DA oxidation and elevated DA-relevant stress in DA neurons, promoting neurodegeneration. When PINK1 is mutated, kinase activity will be impaired causing LRRK2–PINK1 imbalance and disrupting the TH–DA pathway, promoting DA neuron vulnerability and neurodegeneration

    Article Snippet: LRRK2 R1441G TG mice generated from BAC containing the entire human mutant R1441G LRRK2 were also provided by the Jackson Laboratory (#009604) [ ].

    Techniques: Expressing, Functional Assay, Activity Assay

    Journal: eLife

    Article Title: A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation

    doi: 10.7554/eLife.79771

    Figure Lengend Snippet:

    Article Snippet: Recombinant DNA reagent , pCMV5 FLAG-LRRK2 K17A/K18A/R1441G , Addgene RRID: Addgene_186012 , 186012 , Human.

    Techniques: Labeling, Recombinant, Software

    Detection of hLRRK2 and hLRRK2 R1441G expression and GTPase activity in Tg mice. A Real-time PCR assays of hLRRK2 and hLRRK2 R1441G mRNA expression in the brains of Tg mice. Data represent relative mRNA levels (mean ± SEM, n = 8) normalized to mouse apoB and are expressed in arbitrary units. B LRRK2 protein expression in the brains of non-Tg and Tg mice (n = 3). C hLRRK2 R1441G HEM and HOM mice lost less weight than non-Tg mice. Data are presented as the mean ± SEM (n = 6). D GTPase activity was measured using an enzyme-linked inorganic phosphate assay (ELIPA; n = 3). E Disruption of LRRK2 Ser935 phosphorylation in the brains of hLRRK2 , R1441G HOM mice. Total lysates from the brains of 12-month-old hLRRK2 R1441G HOM mice were analyzed by western blotting for phosphorylation of LRRK2 at Ser935; actin was used as a loading control. *Significant effect, p < 0.05; **significant effect, p < 0.01; ***significant effect, p < 0.005; ****significant effect, p < 0.001

    Journal: Journal of Biomedical Science

    Article Title: Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism

    doi: 10.1186/s12929-022-00844-9

    Figure Lengend Snippet: Detection of hLRRK2 and hLRRK2 R1441G expression and GTPase activity in Tg mice. A Real-time PCR assays of hLRRK2 and hLRRK2 R1441G mRNA expression in the brains of Tg mice. Data represent relative mRNA levels (mean ± SEM, n = 8) normalized to mouse apoB and are expressed in arbitrary units. B LRRK2 protein expression in the brains of non-Tg and Tg mice (n = 3). C hLRRK2 R1441G HEM and HOM mice lost less weight than non-Tg mice. Data are presented as the mean ± SEM (n = 6). D GTPase activity was measured using an enzyme-linked inorganic phosphate assay (ELIPA; n = 3). E Disruption of LRRK2 Ser935 phosphorylation in the brains of hLRRK2 , R1441G HOM mice. Total lysates from the brains of 12-month-old hLRRK2 R1441G HOM mice were analyzed by western blotting for phosphorylation of LRRK2 at Ser935; actin was used as a loading control. *Significant effect, p < 0.05; **significant effect, p < 0.01; ***significant effect, p < 0.005; ****significant effect, p < 0.001

    Article Snippet: Hemizygous (HEM) wild-type (WT) hLRRK2 mice (FVB/N-Tg ( LRRK2 )1Cjli/J, no. 009610) [ ], and HEM hLRRK2 R1441G transgenic (Tg) mice (FVB/N-Tg ( LRRK2 *R1441G)135Cjli/J, no. 009604) [ ] were purchased from the Jackson Laboratory and bred on an FVB/N background (Jackson stock number.

    Techniques: Expressing, Activity Assay, Real-time Polymerase Chain Reaction, Disruption, Phospho-proteomics, Western Blot, Control

    Locomotor activity in the open-field test was significantly reduced in hLRRK2 2 R1441G HOM mice. Data are presented as the mean ± SD (n = 5). *Significant effect, p < 0.05; **significant effect, p < 0.01; ***significant effect, p < 0.005; ****significant effect, p < 0.001

    Journal: Journal of Biomedical Science

    Article Title: Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism

    doi: 10.1186/s12929-022-00844-9

    Figure Lengend Snippet: Locomotor activity in the open-field test was significantly reduced in hLRRK2 2 R1441G HOM mice. Data are presented as the mean ± SD (n = 5). *Significant effect, p < 0.05; **significant effect, p < 0.01; ***significant effect, p < 0.005; ****significant effect, p < 0.001

    Article Snippet: Hemizygous (HEM) wild-type (WT) hLRRK2 mice (FVB/N-Tg ( LRRK2 )1Cjli/J, no. 009610) [ ], and HEM hLRRK2 R1441G transgenic (Tg) mice (FVB/N-Tg ( LRRK2 *R1441G)135Cjli/J, no. 009604) [ ] were purchased from the Jackson Laboratory and bred on an FVB/N background (Jackson stock number.

    Techniques: Activity Assay

    Several parameters of measured by the CatWalk system were affected in various ways in four mice. The swing velocity, cadence, and stride length were decreased in hLRRK2 R1441G HOM mice. In contrast, the stance duration and the pressure on the hind-paws BOS increased in hLRRK2 R1441G HOM mice. Data are presented as the mean ± SD (n = 5). *Significant effect, p < 0.05; **significant effect, p < 0.01; ***significant effect, p < 0.005; ****significant effect, p < 0.001

    Journal: Journal of Biomedical Science

    Article Title: Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism

    doi: 10.1186/s12929-022-00844-9

    Figure Lengend Snippet: Several parameters of measured by the CatWalk system were affected in various ways in four mice. The swing velocity, cadence, and stride length were decreased in hLRRK2 R1441G HOM mice. In contrast, the stance duration and the pressure on the hind-paws BOS increased in hLRRK2 R1441G HOM mice. Data are presented as the mean ± SD (n = 5). *Significant effect, p < 0.05; **significant effect, p < 0.01; ***significant effect, p < 0.005; ****significant effect, p < 0.001

    Article Snippet: Hemizygous (HEM) wild-type (WT) hLRRK2 mice (FVB/N-Tg ( LRRK2 )1Cjli/J, no. 009610) [ ], and HEM hLRRK2 R1441G transgenic (Tg) mice (FVB/N-Tg ( LRRK2 *R1441G)135Cjli/J, no. 009604) [ ] were purchased from the Jackson Laboratory and bred on an FVB/N background (Jackson stock number.

    Techniques:

    Comparison of [18F]FDOPA images from four groups of mice, showing significantly decreased uptake of the ligand among Tg mice: A coregistered coronal [ 18 F]FDOPA images of the non-Tg mouse striatum; B coregistered coronal [ 18 F]FDOPA images of the hLRRK2 mouse striatum; C coregistered coronal [ 18 F]FDOPA images of the hLRRK2 R1441G HEM mouse striatum; D coregistered coronal [ 18 F]FDOPA images of the hLRRK2 R1441G HOM mouse striatum; E average [ 18 F]FDOPA uptake in the region of interest (striatum) in various groups. The uptake values are A , B , C , and D for Group 1,2,3, and 4, respectively Data are presented as the mean ± SD (n = 5–6). *Significant effect, p < 0.05; **Significant effect, p < 0.01; ***Significant effect, p < 0.005; ****Significant effect, p < 0.001

    Journal: Journal of Biomedical Science

    Article Title: Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism

    doi: 10.1186/s12929-022-00844-9

    Figure Lengend Snippet: Comparison of [18F]FDOPA images from four groups of mice, showing significantly decreased uptake of the ligand among Tg mice: A coregistered coronal [ 18 F]FDOPA images of the non-Tg mouse striatum; B coregistered coronal [ 18 F]FDOPA images of the hLRRK2 mouse striatum; C coregistered coronal [ 18 F]FDOPA images of the hLRRK2 R1441G HEM mouse striatum; D coregistered coronal [ 18 F]FDOPA images of the hLRRK2 R1441G HOM mouse striatum; E average [ 18 F]FDOPA uptake in the region of interest (striatum) in various groups. The uptake values are A , B , C , and D for Group 1,2,3, and 4, respectively Data are presented as the mean ± SD (n = 5–6). *Significant effect, p < 0.05; **Significant effect, p < 0.01; ***Significant effect, p < 0.005; ****Significant effect, p < 0.001

    Article Snippet: Hemizygous (HEM) wild-type (WT) hLRRK2 mice (FVB/N-Tg ( LRRK2 )1Cjli/J, no. 009610) [ ], and HEM hLRRK2 R1441G transgenic (Tg) mice (FVB/N-Tg ( LRRK2 *R1441G)135Cjli/J, no. 009604) [ ] were purchased from the Jackson Laboratory and bred on an FVB/N background (Jackson stock number.

    Techniques: Comparison

    Effect of SN in hLRRK2 , R1441G HEM and HOM mice SNc region. A Ultrastructural analysis of SN in hLRRK2 , R1441G HEM and HOM mice SNc region. Non-Tg and hLRRK2 represent a healthy mitochondrion; HEM and HOM represent a swollen mitochondrion. Selected regions in different magnification images (I, 10,000×; II, 20,000×). Asterisks indicate shrinkage and matrix condensation. HEM, R1441G HEM; HOM, R1441G HOM. B Western blot analysis of mitochondrial fission proteins in the mitochondrial fraction of the whole brain. Equal loading of the gel is demonstrated with Ponceau S staining for mitochondrial protein fragmentation performed on the blot before immunostaining. B Representative western blot for Drp1 and Fis1 expression. Densitometry of the Drp1 ( C ) and Fis1 ( D ) blots is shown as the fold increase (HEM or HOM hLRRK2 ). The figure shows a representative (of two) experiment. Values are means ± SD. *Significant effect, p < 0.05; **significant effect, p < 0.01; ***significant effect, p < 0.005; ****significant effect, p < 0.001

    Journal: Journal of Biomedical Science

    Article Title: Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism

    doi: 10.1186/s12929-022-00844-9

    Figure Lengend Snippet: Effect of SN in hLRRK2 , R1441G HEM and HOM mice SNc region. A Ultrastructural analysis of SN in hLRRK2 , R1441G HEM and HOM mice SNc region. Non-Tg and hLRRK2 represent a healthy mitochondrion; HEM and HOM represent a swollen mitochondrion. Selected regions in different magnification images (I, 10,000×; II, 20,000×). Asterisks indicate shrinkage and matrix condensation. HEM, R1441G HEM; HOM, R1441G HOM. B Western blot analysis of mitochondrial fission proteins in the mitochondrial fraction of the whole brain. Equal loading of the gel is demonstrated with Ponceau S staining for mitochondrial protein fragmentation performed on the blot before immunostaining. B Representative western blot for Drp1 and Fis1 expression. Densitometry of the Drp1 ( C ) and Fis1 ( D ) blots is shown as the fold increase (HEM or HOM hLRRK2 ). The figure shows a representative (of two) experiment. Values are means ± SD. *Significant effect, p < 0.05; **significant effect, p < 0.01; ***significant effect, p < 0.005; ****significant effect, p < 0.001

    Article Snippet: Hemizygous (HEM) wild-type (WT) hLRRK2 mice (FVB/N-Tg ( LRRK2 )1Cjli/J, no. 009610) [ ], and HEM hLRRK2 R1441G transgenic (Tg) mice (FVB/N-Tg ( LRRK2 *R1441G)135Cjli/J, no. 009604) [ ] were purchased from the Jackson Laboratory and bred on an FVB/N background (Jackson stock number.

    Techniques: Western Blot, Staining, Immunostaining, Expressing

    LRRK2 R1441G HOM mice accumulated more autophagosomes in the SNc. A Transmission electron microscopic images of autophagosomes from the SN of 12-month-old hLRRK2 and R1441G transgenic mice. Selected regions in images at different magnifications (I, 10,000×; II, 20,000×). Arrows indicate autolysosomes, and asterisks indicate autophagosomes. Markers of autophagy (LC3 and p62) in the SNc of hLRRK2 and R1441G transgenic mice were determined by western blotting. p62 undergoes degradation at the early phase of autophagy. p62 in mitochondria serves as an adapter for autophagosome recognition. The data appear to downregulate the autophagy process, as observed by the increasing LC3-II conversion and the accumulation of p62, a marker of autophagic degradation

    Journal: Journal of Biomedical Science

    Article Title: Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism

    doi: 10.1186/s12929-022-00844-9

    Figure Lengend Snippet: LRRK2 R1441G HOM mice accumulated more autophagosomes in the SNc. A Transmission electron microscopic images of autophagosomes from the SN of 12-month-old hLRRK2 and R1441G transgenic mice. Selected regions in images at different magnifications (I, 10,000×; II, 20,000×). Arrows indicate autolysosomes, and asterisks indicate autophagosomes. Markers of autophagy (LC3 and p62) in the SNc of hLRRK2 and R1441G transgenic mice were determined by western blotting. p62 undergoes degradation at the early phase of autophagy. p62 in mitochondria serves as an adapter for autophagosome recognition. The data appear to downregulate the autophagy process, as observed by the increasing LC3-II conversion and the accumulation of p62, a marker of autophagic degradation

    Article Snippet: Hemizygous (HEM) wild-type (WT) hLRRK2 mice (FVB/N-Tg ( LRRK2 )1Cjli/J, no. 009610) [ ], and HEM hLRRK2 R1441G transgenic (Tg) mice (FVB/N-Tg ( LRRK2 *R1441G)135Cjli/J, no. 009604) [ ] were purchased from the Jackson Laboratory and bred on an FVB/N background (Jackson stock number.

    Techniques: Transmission Assay, Transgenic Assay, Western Blot, Marker